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1 Summary 
 
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder and the most 
frequent cause of dementia. To date, there are few approved symptomatic drugs for 
treatment of AD, which show little or no effect on disease progression. Impaired 
intracellular calcium homeostasis is one of the underling mechanisms responsible for 
synaptic dysfunction. In addition, calcium dysregulation is believed to occur early in the 
cascade of events leading to AD. Mutations in presenilins (PS1 and PS2) account for the 
vast majority of early onset familial Alzheimer’s disease cases (FAD). Beside the well-
investigated role of presenilins as the catalytic unit in γ-secretase complex, their 
involvement in regulation of intracellular calcium homeostasis has recently gained 
growing attention in AD research. 
 
In brief, within this study we characterized the role of presenilin mutations in AD-
associated impairment of endoplasmic reticulum (ER) calcium homeostasis. Based on 
those findings, we examined the possibility of pharmacologically reversing the disrupted 
calcium homeostasis in the ER as an innovative approach for AD drug discovery. 
Therefore, we developed a fully automated high-throughput calcium imaging assay 
utilizing a genetically-encoded calcium sensor and subsequently screened a large 
collection of compounds. High-throughput drug screening led to the identification of a 
number of novel drug candidates that were characterized and validated for their relevance 
in AD therapy using a number of secondary assays. 
 
In the first part of this work, we reveal that the overexpression of PS1 full-length 
holoprotein, in particular familial Alzheimer’s disease-causing forms of PS1 (FAD-PS1), 
result in significantly attenuated calcium release from thapsigargin- and bradykinin-
sensitive ER calcium stores. Interestingly, treatment of HEK293 cells with γ-secretase 
inhibitors also lead to decreased amount of calcium release from ER accompanying 
elevated PS1 holoprotein levels. Similarly, the knockdown of PEN-2 that is associated 
with deficient PS1 endoproteolysis and accumulation of its holoprotein form also leads to 
decreased ER calcium release. Notably, we detected enhanced PS1 holoprotein levels in 
postmortem brains of patients harboring FAD-PS1 mutations. Taken together, the 
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conditions in which the amount of full-length PS1 holoprotein is enhanced often resulted 
in decreased calcium release from ER. Based on these results and the proposed leak 
channel activity of presenilins in the ER, we suggest that the disturbed ER calcium 
homeostasis mediated by the elevation of PS1 holoprotein levels may be a contributing 
factor to the pathogenesis of AD. 
 
On the other hand, we also found that FAD-PS1 mutations cause remarkably enhanced 
muscarinic agonist-evoked calcium release from ER, a mechanism that may potentially 
compensate for the lowered ER calcium content. In the second part of the work, we aimed 
at screening compounds that can reverse the potentiated muscarinic agonist-evoked 
calcium release in FAD-PS1-expressing cells, as a robust phenotypic readout. 
Accordingly, we developed a fully automated high-throughput calcium imaging assay 
utilizing a FRET-based calcium indicator at single-cell resolution for compound 
screening. Initially, we employed the developed assay for a pilot screen with a library of 
72 known ion channel ligands. This led to the identification of Bepridil, a calcium 
channel antagonist drug, which was capable of partially reversing the potentiated FAD-
PS1-induced ER calcium release from ER. We detected increased AMPK activity upon 
treatment of cells with Bepridil in a dose-dependent manner. AMPK activation by 
Bepridil is most likely a calcium-dependent phenomenon, since CaMKK inhibition by 
STO-609 abolishes the Bepridil-induced AMPK activation. In accordance with another 
study, we detected lowered Amyloid-β (Aβ) peptide production, increased sAPPα and 
decreased sAPPβ levels upon Bepridil treatment. Therefore, based on the results here, we 
propose a novel calcium-dependent mode of action for Bepridil that through activation of 
AMPK can shift the balance of downstream APP processing from amyloidogenic β-
cleavage towards non-amyloidogenic α-cleavage. 
 
In the third and final part of this work, we performed a truly high-throughput compound 
screen with a diverse library of 20,000 small molecules. This novel screen yielded five 
lead structures identified upon structure-activity-relationship analysis. Amongst them 
were tetrahydrocarbazoles, a novel multifactorial class of compounds that can reverse the 
impaired ER calcium homeostasis. We found that tetrahydrocarbazole lead structure, 
firstly, dampens the potentiated calcium release from ER in HEK293 cells expressing 
FAD-PS1 mutations. Secondly, the lead structure also improves mitochondrial function, 
measured by increased mitochondrial membrane potential. Thirdly, the same lead 
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structure also attenuates the production of Aβ peptides by decreasing the cleavage of 
Amyloid Precursor Protein (APP) by β-secretase, without notably affecting α- and γ-
secretase cleavage activities. Considering tetrahydrocarbazoles’ multiple modes of action 
by addressing three key pathological aspects of AD, this compound class holds promise 
for development of a potentially effective AD drug candidate. 
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2 Introduction 
 
2.1 Alzheimer’s disease 
 
Alzheimer's disease (AD) is the most common form of dementia and a growing threat to 
our aging society [1]. This progressive neurodegenerative disorder is characterized by 
global cognitive decline involving memory, orientation, judgment, and reasoning [2]. The 
estimations suggest that currently over 22 million patients are suffering from AD 
worldwide [1]. AD was described for the first time over a hundred years ago by Alois 
Alzheimer, a German psychiatrist and neuropathologist as "eine eigenartige Erkrankung 
der Hirnrinde" (a peculiar disease of the cerebral cortex) [3]. That work was based on 
monitoring the long-term clinical course of his first AD case Mrs. Auguste Deter, a 51-
year-old lady whom was admitted to Frankfurt community psychiatric hospital for 
paranoia, progressive sleep and memory disturbance, aggression, and confusion [4]. After 
the death of the patient 5 years later, in the microscopic preparations of her brain 
autopsies, Dr. Alzheimer detected the presence of distinctive deposits, which he would 
describe them as “miliary bodies” and “dense bundles of fibrils”, that later respectively 
became known as amyloid plaques and neurofibrillary tangles [3, 5].  
 
The majority of AD cases are sporadic with no obvious implication of genetic factors and 
the typical age of onset older than 65 [6]. Age is the principal risk factor of developing 
sporadic AD [7]. After the age of 65, the overall prevalence of AD doubles every five 
years [8]. However, in less than 1% of AD patients, known as familial Alzheimer’s 
disease (FAD) cases, the dominantly inherited mutations in Amyloid Precursor Protein 
(APP), Presenilin-1 and Presenilin-2 (PS1 and PS2) genes lead to early-onset cases of AD 
[9]. While sporadic and familial AD follow a very similar course, in the case of familial 
AD the disease progression rate is much faster [10]. 
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Figure 2.1. Original microscopic brain preparation of the first AD case described by A. Alzheimer 
The presence of amyloid plaques and neurofibrillary tangles in brain autopsies of Auguste Deter, the first AD 
case described by Alois Alzheimer (Source: Archives of Center for Neuropathology and Prion Research, 
Ludwig Maximilian University of Munich). 
 
 
Today after more than a century from the discovery of AD, despite the countless 
breakthroughs in understanding the underlying mechanisms governing the disease 
progression, the etiology of AD (in particular sporadic AD) remains largely unknown 
[11]. The latter is thought to be one of the reasons for the very little success in the 
development of effective AD therapies [12]. The current AD treatments are very 
insufficient and the few approved AD drugs in the market show symptomatic relief at the 
best and only delay the progression of the disease temporarily [1, 13]. The major 
hallmarks of AD are the accumulation of intracellular neurofibrillary tangles and 
extracellular plaques of amyloid beta (Aβ) protein in the brain [5]. In accordance, the 
current AD drug development strategies mainly focus on targeting these two major 
disease hallmarks [14-16]. However, those events correspond to late stages of AD during 
which the irreversible brain damage has likely already occurred [17]. In view of the 
unsuccessful outcome of all clinical trials with Aβ-targeted drug candidates so far, it is 
suggested that in future clinical trials, drugs should be administrated early enough to 
asymptomatic patients as a preventative measure [18-21]. In addition, it is not fully 
understood whether Aβ plaque and tangle pathologies are the actual causes or rather the 
symptoms of AD [22]. Those are some of the possible reasons for the consistent recent 
failure of disease-modifying drug candidates targeting Aβ and tangle pathologies in late 
clinical phases. 
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2.2 Calcium signaling in health and disease 
 
Calcium is a key second messenger involved in regulation of many physiological and 
pathological processes. Learning and memory, muscle contraction, synaptic transmission, 
secretion, motility, membrane trafficking, excitability, gene expression, and cell division 
are examples of processes that are being regulated by calcium signaling [23]. Therefore 
regulation of calcium homeostasis in space, time and magnitude is essential for the 
cellular function and viability [24]. Neurons maintain this tight regulation through a set of 
machinery consisting of calcium buffers, binding proteins, pumps and sequestering 
mechanisms [25]. The cytosolic calcium concentration is particularly regulated by the 
action of receptor-operated, voltage-gated, and store-operated calcium channels located in 
the plasma or ER membrane. The calcium concentration in the ER lumen is more than 
1000-fold higher than in the cytosol [26]. The basal cytosolic concentration is maintained 
at very low levels (50-300 nM) and only after activation by extracellular influx or from 
intracellular stores, it rapidly reaches low micromolar levels [22]. Too high cytosolic 
calcium concentrations lead to cell death, whereas too low levels impair neuronal 
function [27]. Liberation of calcium from ER into the cytosol is mediated through two 
major calcium channels on the ER membrane, one being inositol-1,4,5- triphosphate 
receptors (IP3R) and the other one Ryanodine receptors (RyR). The IP3R are activated by 
binding of IP3 molecule, which is generated by stimulating G-protein-coupled receptors 
on the plasma membrane by agonists (Figure 3.2). Only in the presence of IP3, calcium 
ions can potentiate the calcium release from IP3R [28]. In addition, RyRs are activated 
directly by calcium ions through a process known as “calcium-induced calcium release” 
(CICR), while substances like caffeine can enhance the sensitivity of RyR to its native 
activator calcium [22, 24, 29, 30]. The tight regulation of ER calcium release is crucial 
for rapid neuronal responses to synaptic inputs, action potentials and synaptic plasticity 
[31]. 
2.3 Impairment of calcium homeostasis in Alzheimer’s disease 
 
Among many different hypotheses, it is believed that calcium dysregulation plays a key 
role in the pathophysiology of AD [22, 32]. Disrupted cellular calcium homeostasis 
impairs synaptic plasticity, mitochondrial function, membrane excitability, APP 
processing, Tau phosphorylation and increases susceptibility to apoptosis, practically all 
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being features of AD [33]. The involvement of calcium dyshomeostasis in the 
pathogenesis of AD has been acknowledged over the last 2 decades [34, 35]. In late 80s 
and early 90s, Zaven Khachaturian postulated a role for disrupted calcium homeostasis in 
aging and pathogenesis of AD. He suggested that lifelong impairment of calcium 
homeostasis eventually results in neurodegeneration [31]. Even prior to that, indirect cues 
indicated the activation of calcium-dependent proteins in postmortem brains of AD 
patients, pointing towards the involvement of calcium in AD pathogenesis [36]. 
Interestingly, Memantine, one of the only few approved drugs for treatment of moderate-
to-severe AD, is an NMDA receptor antagonist, which by inhibition of sustained calcium 
influx leads to stabilization of intracellular calcium homeostasis [37].  
 
Long preceding the manifestation of pathological hallmarks and cognitive deficits in AD 
[25], the intracellular neural calcium homeostasis is likely to be altered due to either 
aging or alternatively by familial Alzheimer’s disease linked mutations in the Presenilin 
genes (FAD-PS) [38-41, 42; discussed in section 3]. It is suggested that age-dependent 
alterations in the calcium homeostasis may lead to altered neuronal excitability, a 
phenomenon similar the effect of FAD-PS mutations [42-45]. Moreover, impaired 
calcium signaling in peripheral tissues was proposed as diagnostic biomarkers of mild AD 
[46, 47]. Notably, alterations in ER calcium channels were found to correlate with 
neurofibrillary and Aβ pathology in AD brain [48]. Furthermore, the long-term disruption 
of calcium homeostasis triggers and accelerates both Aβ and tangle pathologies [39, 49, 
50]. Essentially, AD is believed to be primarily a disorder of synaptic failure [51]. In AD, 
calcium dysregulation is a proximal event in disease progression which plays a key role in 
synaptic failure and neuronal loss [52]. Notably, the latter irreversible pathological events 
correlate best with cognitive loss and the stages of dementia [53, 54]. 
 
2.4 APP processing and amyloid pathology in AD 
 
As indicated in section 2.1, one of the AD hallmarks is the generation of amyloid plaques, 
the extracellular insoluble protein deposits found in the brains of AD patients [55]. The 
major constituent of the amyloid plaques is a 4 kDa peptide called Aβ which can be 
ranging from 36-43 amino acids in length [7]. However, Aβ peptides with 40 or 42 amino 
acids are the most prevalent species [7, 56]. In “amyloid hypothesis”, the accumulation of 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 9 
Aβ because of imbalanced Aβ production, clearance and aggregation, is believed to 
initiate a pathogenic cascade ultimately leading to AD [55]. 
 
After over 20 years since it was proposed, amyloid hypothesis still dominates the AD 
field [57]. However, poor correlation between Aβ deposits and the course of AD, 
substantial differences between early- and late-onset AD cases, pathological assessments 
indicating the secondary nature of lesions/proteins/cascades, poor reproducibility of 
soluble species in the lab, and the irrelevance of synaptic assessment to pathological 
interpretation, are some of the issues which altogether have resulted in a debate as to how 
far this hypothesis shall be pursued in the drug discovery of AD [58]. 
 
Aβ is the product of regulated intramembrane proteolysis (RIP) of Amyloid Precursor 
Protein (APP) [55, 59]. APP is a type I transmembrane protein which can be cleaved by 
three different enzymes: α-secretase and β-secretase in the extracellular domain and γ-
secretase in the transmembrane region [60]. In the amyloidogenic pathway, Aβ is 
generated from the sequential proteolytic cleavage of APP, first at β-site by a β-secretase 
called BACE (β-site APP cleaving enzyme), followed by PS-containing γ-secretase 
complex at the γ-site of APP [32]. Alternatively, in a competing non-amyloidogenic 
pathway, α-secretase can cleave APP at α-site within the Aβ domain to preclude Aβ 
generation [60] (Figure 2.2). 
 
The β-cleavage takes place within the ectodomain of APP in close proximity of the 
transmembrane domain. Soluble APP ectodomain (sAPPβ) and membrane-bound C-
terminal fragment C99 are the products of APP cleavage with β-secretase. Subsequently, 
C99 is cleaved by γ-secretase resulting in secretion of Aβ in the extracellular and the 
formation of the APP intracellular domain (AICD). Alternatively, in the non-
amyloidogenic pathway, from the cleavage of APP with metalloprotease α-secretase, 
soluble APP ectodomain (sAPPα) and a C-terminal fragment (C83) are produced. Next, 
C83 is cleaved by γ-secretase resulting is secretion of p3 peptide (3 kDa) and generation 
of AICD [61, 62] (Figure 2.2). 
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Figure 2.2. APP processing by α-, β- and γ-secretase 
In amyloidogenic processing of APP, Aβ is generated from the sequential cleavage by β-secretase and γ-
secretase. However, in non-amyloidogenic pathway, the cleavage of APP with α-secretase within the Aβ 
domain precludes the formation of Aβ [Adapted from Lichtenthaler et al., Reference number 61]. 
 
Currently most attempts in AD drug development are targeted at Aβ pathology [63]. 
These approaches aim at inhibition or modulation of the proteolytic cleavage of APP in 
order to decrease the neurotoxic Aβ formation, enhance Aβ clearance using 
immunotherapy, influence Aβ aggregation, neutralize Aβ toxicity, or remove existing Aβ 
aggregates [14, 57]. 
 
While our understanding of pathological versus physiological roles of APP and Aβ are 
rather limited [64, 65], there seems to be also a certain level of uncertainty as to which 
type of Aβ is the most relevant species to be targeted in anti-Aβ therapy [66]. In addition, 
it is not fully understood how much decrease in Aβ burden is optimal to yield clinical 
efficacy. Furthermore, many AD clinical trials so far did not address disease modification 
at the right progression stage and with the right AD patient population category [67]. 
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2.5 The interplay between calcium and amyloid pathology in AD 
 
The connection between calcium and Aβ pathology is mutual. Calcium triggers Aβ 
pathology, but also gets triggered by it [49]. The maintenance of low cytosolic calcium 
concentration with respect to extracellular environment and intracellular stores is essential 
for the neuronal function [68]. High cytosolic calcium concentrations, originated either 
from extracellular calcium influx or from intracellular stores increase Aβ production, 
aggregation, and Aβ42:Aβ40 ratio [22, 50, 69-76]. The knockdown of two main 
components of ER calcium homeostasis, namely IP3R and SERCA2b, was shown to 
mediate decreased Aβ generation [69, 72]. How disrupted calcium homeostasis exactly 
contributes to amplified Aβ pathology is not yet fully understood. Nevertheless, it seems 
that calcium affects several factors involved in APP processing. For example, it has been 
demonstrated that calcium can enhance the BACE1 proteolytic activity [39]. 
 
On the other hand, already in early 90s, Mattson and colleagues could show that Aβ 
causes destabilization of neuronal calcium homeostasis and consequently vulnerability to 
excitotoxicity [77]. The role on Aβ in disrupting cellular calcium homeostasis is mainly 
attributed to the stimulated calcium influx from extracellular [78]. Several modes of 
action have been proposed to explain the Aβ-dependent enhanced calcium influx. For 
example Aβ oligomers have been shown to directly form pores on lipid bilayers [79-81], 
disrupt membranes [82, 83], form ROS causing lipid peroxidation [84] or impair 
membrane ATPase activity [85]. Aβ oligomers have been also shown to modulate the 
activity of NMDA receptors [86] and thus lead to NMDA-mediated excitotoxicity [87], 
while on the other hand suppress the activity of P/Q-type voltage-gated calcium channels 
[88]. 2-photon in vivo calcium imaging in AD mouse models has revealed that there are 
clusters of hyperactive neurons and calcium overload in neurites in close proximity of 
senile plaques [89, 90]. On the other hand, a recent study found no correlation between 
the evoked calcium responses and the distance from Aβ plaques in pyramidal 
hippocampal CA1 neurons of an APP/PS1 mouse model of AD [91].  
 
Interestingly upon exposure of cortical neurons with extracellular Aβ42, a specific 
upregulation in RyR3 levels can be detected [92]. The latter seems to play a protective 
role, since the knockdown of RyR3 led to increased neuronal cell death [93]. In contrast, 
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treatment of PC12 expressing FAD-PS cells with dantrolene an inhibitor of RyR 
attenuates glutamate and Aβ-induced toxicity [94, 95]. Remarkably, RyR2 isoform is 
densely expressed in the same brain regions that are most vulnerable in AD pathology, 
particularly hippocampus, whereas the RyR3 isoform has a diffuse and sparse expression 
pattern [96]. Furthermore, a recent study also shows that intracellular application Aβ42 
soluble oligomers (but not monomers) causes release of calcium from IP3Rs, a 
mechanism which may contribute to the cytotoxic effects of Aβ [97]. 
 
In 6-8 week old presymptomatic 3xTg-AD mice, already a selective upregulation of 
RyR2 isoform can be detected [98]. Interestingly at this young age, these mice do not 
show any cognitive or neurophysiological impairment [99]. In agreement with these data, 
RyR2 mRNA levels were shown to be increased in brain samples from patients with 
mild-cognitive-impairment (MCI) compared to individuals with no cognitive impairment 
[100]. Therefore, the upregulation of RyR2 might reflect a compensatory mechanism to 
normalize the disrupted ER calcium homeostasis in order to maintain a healthy neuronal 
transmission and plasticity during presymptomatic stages of the disease. However, 
maintaining this balance over the course of years might influence the disease process. 
Once the chronic calcium assaults overwhelm those neuronal compensatory mechanisms, 
the impairments in synaptic plasticity and LTP become apparent and neurodegeneration is 
likely to occur [101]. On the other hand, high levels of Aβ42 resembling the later stages 
of the disease induce specific upregulation of RyR3 isoform [92]  
 
2.6 Connection between calcium and tau pathology in AD 
 
Another hallmark of AD is the accumulation of neurofibrillary tangles in the brain, which 
are common filamentous inclusions in tauopathies [5, 102]. A strong correlation is found 
between the neurofibrillary tangle pathology and the severity of AD [103, 104]. These 
tangles are mainly composed of paired helical filaments of abnormally 
hyperphosphorylated tau, a microtubule-associated protein [105, 106]. Under 
physiological conditions soluble tau protein is involved in stabilization of axonal 
microtubules, however under pathological conditions tau undergoes aggregation due to 
hyperphosphorylation as a result of imbalanced activity of tau kinases and phosphatases 
[107, 108]. The activity of many kinases associated with tau hyperphoshorylation is 
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calcium-dependent. For example Ca2+/calmodulin-dependent protein kinase II (CaMKII) 
and it downstream target AMP-activated protein kinase (AMPK) are implicated in Tau 
phosphorylation [109]. In addition, calcium ions stimulate proteolytic cleavage of p35 to 
p25 which leads to aberrant activation of kinase 5 (Cdk5), yet another kinase involved in 
tau phosphorylation [110]. Notably, Memantine can inhibit and reverse tau 
hyperphosphorylation [111], presumably by stabilization of disrupted cellular calcium 
homeostasis. Interestingly several proteins involved in calcium signaling are associated 
with tauopathies. Calpains [112], calcineurin [113], transglutaminase [114] and a novel 
EF-hand domain-containing calcium-binding protein [115] are examples of that. Similar 
to the feed-forward relationship between Aβ and calcium, there is also a feed-forward 
relationship between tau hyperphosphorylation tau and increased intracellular calcium 
concentrations. It is suggested that extracellular tau by interacting with muscarinic 
receptors can also promote the release of calcium from ER [116]. This would result in a 
vicious cycle in which the excess calcium triggers the calcium-activated kinases and tau 
hyperphoshphorylation, compromising the integrity of neuronal processes, altering 
signaling cascades, and upregulating cholinergic receptor activation coupled to calcium 
release [41, 117]. 
 
2.7 Mitochondrial dysfunction in Alzheimer’s disease 
 
Mitochondria are dynamic ATP-generating organelles which are responsible for more 
than 90% of cellular energy production [118]. In particular, due to the limited glycolytic 
capacity of neurons and their strong dependence on aerobic oxidative phosphorylation, 
mitochondrial energy production plays an important role in the brain [119]. Mitochondria 
are implicated in many cellular functions including intracellular calcium homeostasis, 
alteration of cellular reduction-oxidation potentials, free radical scavenging and activation 
of caspase-mediated apoptosis [120]. Mitochondria buffer the changes in the local 
calcium concentration proximal to plasma membrane and ER, regulate calcium flux and 
modulate the frequency of calcium oscillations [121]. The mitochondrial calcium uptake 
particularly plays an important role in synaptic transmission at presynapses [122]. 
Both functionally and physically, ER and mitochondria are interdependent. The 
interaction between them is mainly through the zones where the two organelles come into 
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close contact [123]. These zones known as ER-mitochondria-associated-membranes 
(MEM) are loci of calcium shuttling between ER and mitochondria [124], playing an 
important role in many fundamental biological processes [125] (Figure 2.3). Particularly, 
calcium release from IP3R to mitochondria is essential for the maintenance of 
mitochondrial functions [126]. Importantly presenilin mutations have been shown to also 
modulate the shuttling of calcium between ER and mitochondria [127]. Therefore, it is 
plausible that the disruption in the ER calcium homeostasis also affects mitochondrial 
activity. Furthermore, mitochondrial calcium overload is proposed to underlie the 
oligomeric Aβ-induced toxicity, a phenomenon which can be reversed by non-steroidal 
anti-inflammatory drugs (NSAIDs) [128]. 
 
 
Figure 2.3. Shutting of calcium between ER and mitochondria 
Calcium ions are shuttled between ER and mitochondria at the junctions between the two organelles, known 
as ER-mitochondria-associated-membranes (MEM). The shuttling is mediated by the IP3R at the ER 
membrane and the calcium uniporter in the inner mitochondrial membrane [Adapted from Collins et al., 
Reference number 129]. 
 
Mitochondrial dysfunction is a key early event in the course of aging and in the 
pathogenesis many neurodegenerative disorders, including AD [120, 130-135]. Examples 
of AD-associated mitochondrial dysfunctions are decreased number of neuronal 
mitochondria, increased mitochondrial DNA content, lowered glucose metabolism, 
imbalanced mitochondrial fission and fusion, impaired mitochondrial trafficking, and 
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reduced mitochondrial membrane potential [136-140]. The functions of several crucial 
mitochondrial enzymes have been demonstrated to be inhibited by Aβ exposure in brain 
or in isolated mitochondria [141, 142]. Moreover, mitochondrial dysfunction is believed 
to be implicated in the dysfunction and loss of synapses as well as neuronal apoptosis in 
AD [51, 143, 144]. In this context, Aβ has been demonstrated to induce mitochondrial 
dysfunction and morphological changes accompanied by decreased amount of synpatic 
proteins [145]. Morphological studies indicate a strong correlation between mitochondrial 
pathology with dystrophic dendrites, loss of dendritic branches and the pathological 
alteration of the dendritic spines [146]. Therefore, improving mitochondrial function by 
itself is considered as a viable approach in AD drug development [133, 147-149]. 
Recently a drug known as Dimebon (Latrepirdine) made its way to clinical phase III trials 
for AD [150]. Despite its late-stage failure, the beneficial biological effects of Dimebon 
were mainly attributed to improving mitochondrial function [151, 152].  
 
2.8 The therapy of Alzheimer’s disease 
Currently, all of the AD drugs in the market are symptomatic, whereas the drugs in 
development are mostly disease-modifying, in the sense that these novel treatments are 
targeted at the pathological steps leading to AD, with the aim of interfering with the 
evolution of the disease [15].  
 
2.8.1 Symptomatic therapy 
The first drugs developed for AD were acetylcholinesterase inhibitors (AChEI) [15]. 
These drugs were developed on the basis of the cholinergic hypothesis of AD which 
argues that the cholinergic deficits, in particular decreased acetylcholine levels and the 
loss of basal forebrain cholinergic neurons, are implicated in the pathogenesis of AD 
[153]. Currently there are 3 approved AChEIs in the market for treatment of mild-to-
moderate AD patients: Donepezil (Pfizer), Rivastigmine (Novartis) and Galantamine 
(Janssen) [154]. Tacrine (First Horizon Pharmaceuticals) was the first AChEI approved 
drug for treatment of AD in 1993, which is not anymore being used due to the damage it 
causes to the liver [155]. Donepezil is now also approved for treatment of severe AD 
patients in the US [156]. The development of further cholinergic drugs is still ongoing. 
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Apart from AChEIs, Memantine (Merz, Forest, and Lundbeck) is a further symptomatic 
therapeutic option for treatment of moderate-to-severe AD [154]. Memantine is an 
uncompetitive, moderate-affinity NMDA receptor antagonist, which is believed to protect 
neurons from excitotoxicity [15, 154]. 
 
2.8.2 Disease-modifying therapy 
In contrast to the partial success in development of symptomatic drugs for treatment of 
AD, in spite of huge investments towards the development of Alzheimer’s disease-
modifying therapies, the field has faced the consistent failure of disease-modifying 
approaches for AD in preclinical and clinical phases [20]. 
 
2.8.2.1 Amyloid-targeted therapies 
On the basis of the widely accepted amyloid hypothesis of AD and its central role in the 
diagnosis of the disease, the majority of disease-modifying approaches have largely 
focused on the development of medicines targeting Aβ pathology [154]. In essence, such 
approaches suggest that excessive levels of Aβ in its different forms, e.g. plaques, soluble 
oligomers, fibrils, protofibrils… play a causative role in the pathogenesis of AD. 
Therefore, the removal of such neurotoxic Aβ should results in clinical efficacy. Here, we 
try to summarize the most important therapeutic interventions targeting Aβ pathology. 
 
2.8.2.1.1 β-secretase inhibitors 
Since the first step in APP processing is the β-secretase cleavage, several BACE1 inhibitors have 
been developed as potential therapeutics for AD. However, BACE1 inhibition turns out to be a 
challenging approach for two major reasons: Firstly, BACE1 cleaves many substrates 
beside APP with important physiological roles. Therefore, BACE1 inhibition may cause 
undesired toxic side effects. Secondly, BACE1 has a relatively wide active site. 
Therefore, BACE1 inhibitors are often bulky molecules that do not readily cross the 
blood-brain barrier [14, 154]. 
Due to such difficulties, only a small number of BACE1 inhibitors entered early clinical 
trials while the majority of β-secretase inhibitors are still in preclinical stages [157]. 
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2.8.2.1.2 γ-secretase inhibitors and modulators 
γ-secretase is a multiprotein complex inside of which presenilins (PS1 and PS2) are 
responsible for the final enzymatic cleavage of APP that results in formation of Aβ. 
Similar to β-secretase, γ-secretase also cleaves many transmembrane protein substrates. 
Accordingly, γ-secretase inhibition was shown to be associated with side-effects which 
are often related to Notch signaling [158]. Although, several γ-secretase inhibitors 
reached clinical trials, their late clinical trials were often prematurely interrupted due to 
toxicity and detrimental effects on cognition and functionality of treated patients. Those 
side effects are believed to be caused by impaired Notch processing and accumulation of 
neurotoxic APP-CTF [159]. More recently, γ-secretase inhibitors with high selectivity to 
APP are being developed [160]. 
In addition, a particular focus has been put towards the development of γ-secretase 
modulators (GSMs). GSMs specifically lower the production of amyloidogenic Aβ42 
peptides, while increasing the production of shorter Aβ species (e.g. Aβ38) [158, 159, 
161]. Importantly, GSMs alter APP processing without the Notch-based adverse effects 
[14]. A subset of non-steroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, 
indomethacin, and sulindac sulfide, were shown to possess the properties of GSMs [14, 
15, 154]. 
2.8.2.1.3 α-secretase activators 
Enhancing α-secretase activity and shifting APP processing towards non-amyloidogenic 
pathway results in decreased Aβ production and increased levels of neuroprotective 
sAPPα peptide [64, 162]. Therefore, stimulating α-secretase activity has been regarded as 
a valuable approach in AD drug development [163]. Although several α-secretase 
activators failed to show desired clinical efficacy, encouraging safety results support the 
development of further α-secretase activators with improved clinical efficacies [15, 164]. 
2.8.2.1.4 Anti Aβ aggregation drugs 
The hypothesis that Aβ aggregation leads to formation of oligomeric Aβ species that 
impair synaptic function and plasticity has led to development of drugs which are aimed 
at preventing Aβ aggregation or destabilizing Aβ oligomers [14]. Glycosaminoglycans 
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that binds to Aβ monomers and prevent oligomer formation [165], zinc- and copper-
chelating compounds which dissolve amyloid deposits [14, 15, 166], and scyllo-inositols 
which directly bind to Aβ oligomers and promote the dissociation of Aβ aggregates are 
examples of such drugs [167, 168]. Based on the lack of clear-cut clinical efficacy results, 
large-scale phase 3 clinical studies are required in order to better evaluate the potential of 
anti-Aβ aggregation agents as AD therapeutics [14, 15, 154, 162, 168]. 
2.8.2.1.5 Immunotherapy 
Both active immunization (vaccination) and passive immunization (monoclonal 
antibodies) are regarded as promising approaches that aim at increasing Aβ clearance 
which may potentially affect Aβ production, aggregation and deposition [162, 169]. In 
active immunization, the immune system is stimulated to promote formation of antibodies 
against pathogenic forms of Aβ, whereas in passive immunotherapy antibodies are 
delivered exogenously [169]. Although a number of immunotherapy approaches were 
associated with adverse side effects [14, 170-172], currently several antibodies are under 
investigation in clinical and preclinical phases for AD [14, 15, 154, 173]. 
 
2.8.2.2 Tau-targeted therapies 
 
On the basis of the hypothesis that tau pathology strongly contributes to the pathogenesis 
of AD and its strong correlation with the stage of the disease, a number of tau-targeted 
AD therapeutic approaches are being developed [107, 174]. Amongst them are drugs in 
clinical trials which are interfering with either tau aggregation or phosphorylation [154, 
175-178]. Based on recent immunization studies in AD mouse models, both tau 
vaccination and the use of tau antibodies were proposed as potential AD therapeutic 
modalities [179-181]. However, given the fact that tau is an intracellular protein, 
development of a successful tau immunotherapy appears to be rather challenging [15]. 
 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 19 
2.8.2.3 Alternative therapies 
 
Stem cells, neurotrophins, enhancers of mitochondrial function, anti-inflammatory 
medications, antioxidants, neuroprotective agents, as well as drugs modulating cholesterol 
and vascular-related risk factors are some of the alternative approaches currently being 
investigated in preclinical and clinical stages for AD therapy [14, 154, 162]. 
 
2.9 The development status of calcium signaling-targeted therapies for AD 
 
2.9.1 Pharmacological modulation of extracellular calcium flux 
 
2.9.1.1 Receptor-operated calcium channels (ROCC) 
 
Despite efforts in drug discovery and development of ion channel blockers and their 
promising results in AD animal models, memantine remains to be the first and only 
clinically approved drug in Europe and North America for treatment of moderate-to-
severe AD patients [37, 182, 183]. The beneficial effects of memantine are only marginal 
[184], however, they are attributed to blockage of NMDA receptor and thus restoring the 
excess calcium influx to physiological levels. This results in lowered cytosolic calcium 
concentration, enhanced CCE and increased ER calcium load and in turn potentiated 
agonist-induced calcium release [185]. EVT 101, a NR2B-selective NMDA receptor 
antagonist, is currently in clinical trials for AD [186].  
 
Aβ42 (but not Aβ40), has been shown to interact and exert inhibitory effects on synaptic 
AMPA receptors, a phenomenon which may contribute to AD-associated memory 
impairments [187]. This finding provides an explanation for the observed downscaling of 
AMPA receptor activity accompanied with memory impairments in APP/PS1 double 
knock-in AD mouse model [188, 189]. Indeed AMPA receptor activators have been 
shown to reverse the age-associated memory loss and improve learning in rats, however 
with no efficacy in AD patients [190]. Interestingly, Dimebon apart from improving 
mitochondrial activity was shown to block NMDA receptors and potentiate the activity of 
AMPA receptors as well [191].  
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2.9.1.2 Voltage-gated calcium channels (VGCC) 
 
The involvement of VGCCs in AD is known for quite some time. Aβ has been shown to 
enhance calcium influx through L-type VGCCs [192]. Therefore blocking VGCC is an 
interesting target for AD therapy [193]. Nimodipine (an L-type calcium channel 
antagonist) has been shown to attenuate the neurotoxicity mediated by Aβ-induced 
potentiation of calcium influx [192] and Aβ accumulation caused by neuronal 
depolarization and increased cytosolic calcium concentration [74]. However due to mixed 
results in terms of clinical efficacy of Nimodipine in AD and other dementias, its 
usefulness still a matter of debate [194]. MEM 1003 is a Nimodipine-related compound, 
which is currently in late clinical trials for AD [195, 196]. 
 
Nimmrich et al. demonstrated that Aβ oligomers can impair presynaptic P/Q-type 
calcium currents at both GABAergic and glutamatergic synapses [88]. Roscovitine is a 
drug which was shown to enhance the P/Q-type calcium currents [197] and rescue the 
impaired vesicle trafficking in hippocampal neurons induced by Aβ oligomers [88].  
 
2.9.2 Pharmacological modulation of ER calcium signaling 
 
Manipulating ER calcium homeostasis in the context of clinical therapeutics has been so 
far only rarely investigated and never examined for neurodegenerative diseases. 
Modulation of the elements involved in the ER calcium homeostasis has been tested in 
cell culture. Blockade of SERCA pump with Thapsigargin led to increased cytosolic 
calcium concentration through blocking calcium uptake into ER, caspase-3 activation and 
thus enhanced apoptosis. Similarly, Aβ-induced apoptosis is also associated with 
increased cytosolic calcium concentration and capase-3 activity [198]. However, 
SERCA2b loss of function by siRNA knockdown or pharmacologically by Thapsigargin 
or CPA was shown to lower Aβ levels [72, 199] 
 
Blockade of IP3R with Xestosponginn B or C, and RyR with dantrolene restores the 
elevated cytosolic calcium concentrations and protects against Aβ-induced apoptosis 
[200, 201]. On the other hand, treatment with Caffeine sensitizes FAD-PS1 expressing 
neurons to Aβ-induced apoptosis [202]. Genetic ablation of IP3R in cells expressing 
FAD-PS1 also results in remarkable reduction in Aβ levels [69]. Indeed, pharmacological 
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normalization of disrupted ER calcium signaling by blocking hyperactivated RyR 
channels with dantrolene was demonstrated to restore synaptic transmission and synaptic 
plasticity, reduce memory deficits and Aβ burden, increase PSD-95 expression, and 
improve learning and memory in different AD mouse models [203-205]. By contrast, 
another study shows that long-term feeding of dantrolene to APP/PS1 mice [206], results 
in increased Aβ-load accompanied with synaptic marker loss and atrophies in 
hippocampus and cortex [207]. Notably, dantrolene has been already used for treatment 
of malignant hypothermia, neuroleptic malignant syndrome, muscle spasticity and ecstasy 
intoxication. Procaine and tetracaine, two other inhibitors of RyR have been used as local 
anesthetics. Benzothiazepine K201, a RyR-stabilizing compound is being tested for 
treatment of defective RyR channel gating conditions, such as heart failure and kidney 
disease [208]. Therefore, therapeutic modalities aiming at manipulation of ER calcium 
homeostasis present a novel strategy for treatment a wide range of diseases.  
 
2.10 Calcium Imaging 
 
Calcium imaging is technique to monitor and quantify the calcium concentrations and 
calcium dynamics in the living cells. This is achieved through the use of either synthetic 
organic molecules with selective affinity to calcium (calcium dyes) or genetically 
engineered calcium indicators (GECIs) [209]. Both of these methods rely on the changes 
in fluorescence properties of the indicator upon calcium binding. Calcium indicators can 
be either single-wavelength or ratiometric. The advantage of ratiometric indicators is the 
distinct emission (or excitation) properties in calcium-free and calcium-bound states, 
which minimizes the risk of artifacts.  
The concept of using Green Fluorescent Protein (GFP) as biosensors was employed in 
development of genetically engineered calcium indicators as well. Two important classes 
of GECIs are either FRET (Förster Resonance Energy Transfer)-based or single-emission 
calcium indicators [210]. Cameleons are a subclass of FRET-based calcium sensor fusion 
proteins that consist of cyan (CFP) and yellow (YFP) fluorescent protein domains, which 
are linked by calmodulin (CaM), the calmodulin-binding peptide M13 (Figure 6.2a). 
Binding of calcium to CaM results in the conformational change of CaM causing 
wrapping around the M13 domain and thus increasing the FRET between CFP and YFP 
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[211]. In single-emission calcium indicators, the change in the fluorescence intensity of a 
single fluorescent protein is proportional to the amount and change in the calcium 
concentration [210]. Yellow Cameleon 3.6. (YC3.6) is a bright FRET-based calcium 
indicator with about 6-fold wide dynamic range and thus an enhanced signal-to-noise 
ratio [212]. It is photostable and absorbs a great amount of light.  
The advantage of genetically engineered calcium probes compared to synthetic organic 
dyes is the possibility to perform long-term calcium imaging without the drawbacks 
involved in dye loading, washing and leakage, therefore making it ideal for high-
throughput calcium imaging. In addition, in contrast to synthetic calcium dyes, it possible 
to target GECIs to specific compartments and generate stable lines or transgenic animals 
expressing the calcium sensor.  
Opera®, a high-throughput confocal laser scanning imaging system (PerkinElmer), was 
used for calcium imaging in the present work. It combines high sub-cellular resolution 
and speed, in combination with flexible image analysis software, Acapella® [213]. The 
system includes an on-board dispensing unit suitable for applying small drug volumes 
while imaging live cells under environmental control of temperature, CO2 and humidity. 
High resolution is achieved by using confocal imaging and water immersion lenses 
creating an optimal reader for calcium imaging based high-throughput screening. We 
equipped the Opera® system with Bravo® (Agilent technologies), an automated liquid 
handling robot, which works under a laminar flow hood and suitable for sterile cell based 
assays. 
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3.1 Abstract 
 
Mutations in presenilins are responsible for the vast majority of early-onset familial 
Alzheimer’s disease cases. Full-length presenilin structure is composed of nine 
transmembrane domains, which are localized on the endoplasmic reticulum membrane. 
Upon endoproteolytic cleavage, presenilins assemble into the γ-secretase multiprotein 
complex and subsequently get transported to the cell surface. There is a wealth of 
knowledge around the role of presenilins as the catalytic component of γ-secretase, their 
involvement in amyloid precursor protein processing and generation of neurotoxic β-
amyloid species. However, recent findings have revealed a wide range of γ-secretase-
independent presenilin functions, including involvement in calcium homeostasis. 
Particularly, familial Alzheimer’s disease presenilin mutations have been shown to 
interfere with the function of several molecular elements involved in endoplasmic 
reticulum calcium homeostasis. Presenilins modulate the activity of IP3 and Ryanodine 
receptor channels, regulate SERCA pump function, affect capacitative calcium entry and 
function per se as endoplasmic reticulum calcium leak conductance pores. 
 
 
Keywords: Presenilin, Calcium, Endoplasmic reticulum, Alzheimer’s disease 
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3.2 Introduction 
 
Presenilin (PS) mutations account for over 90% of human familial Alzheimer’s disease 
(FAD) cases. Beyond the intensively characterized role of PS as the catalytic core of γ-
secretase multimeric enzyme complex [214], presenilins have been shown to be 
implicated also in a wide range of γ-secretase-independent functions including β-catenin 
regulation, signal transduction, cell adhesion, protein trafficking and turnover, apoptosis, 
synaptic function, tau phosphorylation and calcium homeostasis [215]. γ-secretase is 
responsible for the regulated intramembrane proteolysis (RIP) of over 60 different 
substrates, including amyloid precursor protein (APP) and Notch. Yet, γ-secretase is best 
known for its involvement in formation of β-amyloid (Aβ) peptide, which is generated 
from sequential proteolytic cleavage of APP in Alzheimer’s disease (AD) [214]. The 
discovery of PS came from the work of Sherrington and colleagues in 1995. Their 
genome-wide screen revealed that missense mutations in the PS1 gene (originally known 
as S182) lead to early-onset FAD cases [216]. This finding was shortly complemented by 
an independent study which reported that the PS1 homologous gene in Caenorhabditis 
elegans (sel-12) is implicated in Notch signaling [217]. Meanwhile, PS homologues have 
been identified in several other species, ranging from mammals to frogs, flies, worms, 
fish and plants [218]. PS1 and PS2 are the two highly homologous forms of PS in 
mammals which are respectively located on chromosomes 14q24.3 and 1q42.2 [214]. In 
this review article, we mainly highlight the role of PS in the context of calcium signaling, 
particularly in relation to disrupted calcium homeostasis implicated in the pathogenesis of 
Alzheimer’s disease (AD). 
 
3.3 Structure 
 
Although the crystal structure of PS is not yet resolved, there is strong evidence in favor 
of a nine transmembrane domain (TMD) structure model (Figure 3.1). PS holoprotein is 
~50 kDa in size which undergoes endoproteolysis within a putatively large intracellular 
loop between TMD6 and TMD7 to generate a ~30 kDa N-terminal fragment (NTF) and a 
~20 kDa C-terminal fragment (CTF) which remain associated as a heterodimer [214]. 
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NMR studies could only determine the structure of PS1-CTF, containing a half-
membrane-spanning helix, a severely kinked helical structure toward the carboxyl 
terminus as well as a soluble helix in the unstructured amino-terminal loop of the CTF 
[219]. Despite the lack of NMR structure for PS1-NTF, it is generally agreed upon that 
the PS1-NTF has a classical transmembrane topology consisting of six α-helices. 
 
3.4 Expression, activation and turnover 
 
The expression of both PS1 and PS2 is detectable throughout the brain, in most adult 
human tissues and regulated during development [218]. PS is primarily localized to the 
ER and Golgi apparatus, but also a small fraction is located at the cell surface [218] 
(Figure 3.2). In the brain, endogenous PS is predominantly present as N- and C-terminal 
fragments, while the immature precursor full-length PS holoprotein (PS-FL) is only 
faintly detectable. This is also reflected by the short half-life (~1.5 h) and rapid turnover 
of PS-FL compared to its more stable endoproteolytic fragments with longer half-lives 
(~24 h) [220]. However, upon PS overexpression, the NTF and CTF levels reach a 
saturation threshold, beyond which PS-FL gets accumulated [218]. The proteasomal 
pathway is responsible for the degradation of PS-FL [221]. Endoproteolytic cleavage of 
PS-FL occurs primarily within the ER. Upon association of PS proteolytic fragments with 
three other ER transmembrane proteins (Nicastrin, Aph-1 and Pen-2), a complex is 
formed and subsequently transported to the Golgi through several vesicular transport 
cycles and trafficked to the plasma membrane where it functions as γ-secretase [214].  
 
3.5 Role in calcium homeostasis 
 
In 1994, the involvement of PS in ER calcium signaling was demonstrated for the first 
time. Ito and colleagues observed exaggerated agonist-evoked calcium release from IP3 
receptor (IP3R) channels in fibroblasts from AD patients harboring FAD-PS mutations 
[222]. Guo and colleagues confirmed those data in neuronal-like cells. They observed 
remarkably enhanced IP3R-evoked calcium responses in PC12 cells expressing FAD-PS1 
compared to those expressing wildtype PS1 [223]. Numerous follow-up studies have 
confirmed FAD-PS-mediated excessive ER calcium release in other models including 
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Xenopus oocytes [224], primary neuronal culture [202], acutely dissociated neurons [225] 
and brain slices of adult FAD-PS1 mice [226]. In addition to the greater magnitude of 
IP3R-evoked calcium release, remarkable increase in the percentage of stimuli-responsive 
cells accompanied expression of FAD-PS1 [226]. Using PS-DKO MEF cells (PS1 and 
PS2 double knock out mouse embryonic fibroblasts) of the same origin, inconsistent 
results have been obtained describing either attenuated [227] or amplified [228] calcium 
release from ER. Etcheberrigaray et al. detected an altered IP3R-mediated calcium release 
in fibroblasts from a large proportion of AD family members prior to the appearance of 
overt AD clinical symptoms, but not in family member subjects who failed to develop 
AD [229]. These data supported the “calcium hypothesis” of AD and led to many follow-
up studies, which aimed to mechanistically explore the role of FAD-PS mutations in 
potentiating ER calcium release, which will be discussed later. 
 
Interestingly, calcium release from Ryanodine receptors (RyR) was also potentiated as a 
consequence of FAD-PS expression (Figure 3.2). In PC12 cells and primary hippocampal 
neurons, upregulation of RyR expression level and enhanced RyR-evoked calcium release 
by caffeine was observed [202]. Likewise, RyR-evoked calcium responses were amplified 
in slices from young, adult and aged FAD-PS1 knock-in mice, accompanying increased 
RyR expression [230]. This effect was most remarkable in dendrites and particularly in 
dendritic spines, but also detectable in soma and perinuclear regions [98]. From the 
earlier studies taken together, the “calcium overload” hypothesis was proposed arguing 
that the ER calcium overload is the cause of excessive ER calcium release. The 
interesting finding of the Bezprozvanny group, that PS holoprotein forms passive calcium 
leak channels on planar lipid bilayers and the leak activity to be impaired by FAD-PS 
mutations, came in support of the “calcium overload” hypothesis [228]. They argue that 
RyR upregulation in FAD-PS cells is a neuroprotective compensatory mechanism to 
normalize the overloaded ER calcium levels [207]. They hypothesize that the hydrophilic 
water-filled catalytic cavity of PS may function as a low conductance calcium-permeable 
pore [231]. They also demonstrated a correlation between the effects of FAD-PS 
mutations in terms of the leak activity and different AD clinical phenotypes by calcium 
imaging of patient-derived lymphoblasts [40]. However, more recent data have 
challenged the PS “leak channel” theory [232] and “calcium overload” hypothesis. [69, 
233]. Using several different cell lines and various calcium imaging protocols and 
indicators, the Foskett team investigated ER calcium filling rates, steady-state ER calcium 
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levels and calcium leak rates from ER. However, they could not provide consistent 
supporting evidence in favor of “leak channel” hypothesis [232]. The results from their 
study and several other recent works indicate that FAD-PS mutations lead to an 
unchanged or even attenuated ER calcium level by directly monitoring the absolute 
calcium content of the ER [69, 232-234]. 
 
The FAD-PS mutations do not seem to change the abundance or distribution of IP3 
receptors. However, single IP3R channel recordings in FAD-patient-derived lymphoblasts 
and Sf9 cells have revealed that through physical and functional interaction of IP3R 
channels with FAD-PS holoprotein, IP3Rs become more sensitive. The direct 
consequence of this is the excessive calcium release from ER even under resting 
conditions and sub-threshold IP3 molecule levels, i.e. calcium leakage in the absence of 
muscarinic receptor agonists [69] (Figure 3.2). FAD-PS mutations exert their stimulatory 
effect by enhancing the modal gating activity of IP3R and shifting the balance towards 
burst mode with high open-probability and repetitive openings and away from closed-
probability mode with only brief openings [69, 235]. Similarly, PS2-NTF facilitates the 
single channel activity of mouse brain RyR through its direct physical interaction with 
RyR at the cytosolic side of the ER membrane [236]. This interaction seems to play a role 
in modulating neurotransmitter release in hippocampus, as it was shown that specific 
inactivation of PS at presynapses (but not postsynpases) impairs glutamate release, 
synaptic facilitation and LTP, suggesting a primary role for presynaptic pathomechanisms 
in AD initiation [237]. Intracellular store calcium handling plays a crucial role in synaptic 
function. Indeed, several genetic and electrophysiological studies have pointed towards 
the role of PS in synaptic plasticity. Since PS associates with NMDA receptors, PS-DKO 
mice present lowered synaptic NMDA receptor levels, synaptic and memory deficits as 
well as neurodegeneration with increasing age [238]. In young presymptomatic 3xTg-AD 
mouse model, enhanced calcium release from RyRs accompanies subtle alterations in 
mechanisms underlying hippocampal synaptic transmission, which are typically masked 
by compensatory factors in early disease stages and only detectable under RyR blockade 
conditions [98]. Moreover, hippocampal neuronal cultures from PS1 knockout and PS1-
M146V mice show disrupted homeostatic synaptic scaling of excitatory synapses, which 
reflects disturbances in the neuronal ability to tune with changes in the network activity 
[239]. Furthermore, we have demonstrated that PS1 influences the structural plasticity of 
postsynaptic dendritic spines in the somatosensory cortex [240]. 
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Calsenilin and calmyrin are further proteins involved in ER calcium homeostasis, which 
have been also shown to interact with presenilins [241, 242]. Coexpression of calsenilin 
reverses the FAD-PS specific potentiation of IP3R-evoked calcium release [243]. FAD-PS 
mutations have been shown to increase the neuronal vulnerability to Aβ and glutamate 
through activation of caspase-3 as a result of RyR3 isoform upregulation and enhanced 
RyR-mediated calcium release [244]. 
 
FAD-PS mutations have been shown to increase the neuronal vulnerability to Aβ and 
glutamate through caspase-3 activation as a result of RyR3 isoform upregulation and 
enhanced RyR-mediated calcium release in PC12 cells [244]. Notably, the FAD-PS 
mediated vulnerability and apoptosis can be normalized by pharmacologically or 
functionally inhibiting the IP3R-CaMKIV-CREB pathway in SH-SY5Y cells [201]. In 
PS-DKO MEFs, the expression of IP3R was remarkably upregulated [227]. Moreover, 
FAD-PS mutations lead to enhanced basal activity of phospholipase C (PLC) in SH-
SY5Y cells, which in turn result in increased production of IP3 molecule, mediating 
amplified calcium release from IP3R channels [200] (Figure 3.2). Therefore, it is crucial 
to distinguish the FAD-PS-mediated excessive calcium release as a result of IP3R/RyR 
hyperactivity from ER “calcium overload”. 
 
In fibroblasts, the interaction of PS and SERCA2b was demonstrated by their 
colocalization and coimmunoprecipitation [72]. This interaction is required for the 
regulation of the SERCA pump activity. The same study shows that Xenopus oocytes 
harboring FAD-PS1 more effectively sequester calcium from cytosol into the ER than 
oocytes expressing wildtype PS1 protein [72] (Figure 3.2). In contrast, another study in 
MEFs and SH-SY5Y cells claims that both wildtype PS2 and FAD-PS2 reduce the 
SERCA2b activity [233]. 
 
Capacitive calcium entry (CCE) is the process of refilling intracellular calcium stores 
through store-operated calcium channels (SOCC) on the plasma membrane. Calcium 
imaging in SH-SY5Y cells and primary neurons revealed that CCE is attenuated as a 
result of FAD-PS mutations and potentiated as a result of PS knockout or deficiency [245, 
246] (Figure 3.2). Bojarksi et al. found altered expression levels of STIMs, key proteins 
involved in CCE, in PS-DKO MEFs and patient-derived B-lymphocytes expressing FAD-
PS mutations [247]. 
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As reviewed, the exact mechanism responsible for the FAD-PS mediated amplified ER 
calcium release is still controversial. However, the consequence of this phenomenon is 
the elevation of cytosolic calcium concentration and enhanced neuronal vulnerability to 
stressors. Because calcium itself is the co-agonist of both IP3R and RyR, the elevated 
cytosolic calcium concentration in turn initiates a long-term feed-forward mechanism 
causing a vicious cycle in which the calcium waves and calcium-induced calcium release 
(CICR) become increasingly exaggerated in space, time, and amplitude. 
 
3.6 PS as a therapeutic target for Alzheimer’s disease treatment 
 
Since PS forms the catalytic component of γ-secretase, inhibition or modulation of its 
function serves as the prime therapeutic target for AD drug candidates interfering with Aβ 
generation. However, in view of the unexceptional failures of recent Aβ-focused therapies 
in clinical trials and the emerging non-proteolytic PS functions, future PS-targeted 
therapies should not only focus on interfering with γ-secretase proteolytic activity, but 
rather address the broad spectrum of PS functions, particularly those implicated in the 
pathogenesis of AD (e.g. disrupted calcium homeostasis). 
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Figure 3.1. Schematic representation of human PS1 structure 
PS1 holoprotrein is proposed to consist of nine TM domains on the ER membrane. PS1 undergoes 
endoproteolytic cleavage at a large cytosolic loop between TMD6 and TMD7 to generate N- and C-terminal 
fragments. 
 
 
Figure 3.2. Physiological versus pathological FAD-PS-mediated ER calcium homeostasis 
Calcium concentration in the ER is approximately 1000 folds higher than cytosol. FAD-PS mutations (lower 
panel) potentiate the IP3R- and RyR-induced calcium release, upregulate RyR expression, increase PLC 
basal activity and IP3 molecule generation, enhance SERCA pump function and attenuate CCE, as 
compared to wildtype PS (upper panel). Moreover, PS-FL holoprotein per se may function as passive 
calcium leak channel on the ER membrane, while most FAD-PS mutations lead to the loss of this activity. 
The direction and the size of the arrows respectively represent the direction and amount of calcium 
mobilization. 
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4 Aim of the study 
 
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder and the most 
frequent cause of dementia. The current AD drugs in the market are purely symptomatic, 
with little or no effect on the disease progression. Moreover, the recent failure in 
development of disease-modifying therapies for AD (which were largely targeted at 
amyloid and tangle pathologies) justifies the importance of a shift towards alternative 
novel drug targets. Based on the hypothesis that impaired intracellular calcium 
homeostasis is an early event in AD progression, which is also likely to underlie the AD-
associated synaptic dysfunction, here we aimed at development of calcium signaling-
targeted therapeutic modalities for treatment and/or prevention of AD. 
In brief, the goal of this project was to characterize the disturbances in the endoplasmic 
reticulum (ER) calcium homeostasis in AD, and to address the latter pathophysiological 
phenomenon as a therapeutic target for disease-modifying drug discovery of AD. To that 
end, the specific aims of this thesis were: 
(i) Investigation of the role presenilin (PS) holoprotein upregulation in the 
impairment of ER calcium homeostasis in AD. 
(ii) Development of a novel FRET-based high-throughput calcium imaging assay 
for a phenotypic drug screening targeted at ER calcium dyshomeostasis. 
Screening aimed at identification of compounds that reverse the impaired ER 
calcium signaling phenotype associated with FAD-linked PS mutations. 
(iii) Implementation of the high-throughput calcium imaging assay for a large-
scale primary compound screen with a library of over 20,000 small molecules 
and identification active hits and lead structures. 
(iv) Validation and characterization of the identified lead structures using multiple 
AD-relevant secondary assays. 
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5.1 Abstract 
 
Mutations in presenilins (PS1 and PS2) account for the vast majority of early onset 
familial Alzheimer’s disease cases. Beside the well investigated role of presenilins as the 
catalytic unit in γ-secretase complex, their involvement in regulation of intracellular 
calcium homeostasis has recently come into more focus of Alzheimer’s disease research. 
Here we report that the overexpression of PS1 full-length holoprotein forms, in particular 
familial Alzheimer’s disease-causing forms of PS1, result in significantly attenuated 
calcium release from thapsigargin- and bradykinin-sensitive stores. Interestingly, 
treatment of HEK293 cells with γ-secretase inhibitors also leads to decreased amount of 
calcium release from endoplasmic reticulum (ER) accompanying elevated PS1 
holoprotein levels. Similarly, the knockdown of PEN-2 which is associated with deficient 
PS1 endoproteolysis and accumulation of its holoprotein form also leads to decreased ER 
calcium release. Notably, we detected enhanced PS1 holoprotein levels also in 
postmortem brains of patients carrying familial Alzheimer’s disease PS1 mutations. 
Taken together, the conditions in which the amount of full length PS1 holoprotein is 
increased result in reduction of calcium release from ER. Based on these results, we 
propose that the disturbed ER calcium homeostasis mediated by the elevation of PS1 
holoprotein levels may be a contributing factor to the pathogenesis of Alzheimer’s 
disease. 
 
 
Keywords: Presenilin, Holoprotein, Calcium, Alzheimer’s disease, Endoplasmic 
Reticulum 
 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 37 
5.2 Introduction 
 
Alzheimer’s disease (AD) is the most common form of adult dementia characterized by 
the extracellular accumulation of amyloid beta (Aβ) protein and formation of intracellular 
neurofibrillary tangles leading to neuronal dystrophy and loss [13, 248]. Mutations in 
presenilins (PS) account for the majority of early onset familial Alzheimer’s disease 
(FAD) cases [249]. Upon undergoing endoproteolytic processing and forming N- and C-
terminal fragments (NTF and CTF), PS functions as the catalytic subunit of γ-secretase 
multiprotein complex on the cell surface, comprising PS, Nicastrin, Aph-1, and PEN-2 
[250]. Among over 60 different type I transmembrane protein substrates, γ-secretase 
sequentially cleaves amyloid precursor protein (APP) after β-secretase cleavage to 
generate Aβ [251]. FAD mutations in PS have been shown to alter the cleavage of APP in 
favor of neurotoxic Aβ42 generation [252]. However growing body of evidence also 
indicates that FAD-PS mutations impair several intracellular calcium signaling 
mechanisms, particularly endoplasmic reticulum (ER) calcium homeostasis [22, 253]. 
Uncleaved full-length (FL) PS holoprotein is approximately 50 kDa in size and primarily 
located on the ER membrane [254]. ER calcium store has approximately 1000-fold higher 
calcium concentration than cytosol [26]. The exact molecular mechanism as to how FAD-
PS mutations cause ER calcium dyshomeostasis is not fully resolved. Yet PS have been 
shown to affect multiple components of ER calcium handling [255]. PS holoprotein has 
been proposed to form passive calcium leak channel on the ER membrane [228, 256] 
through its hydrophilic catalytic cavity [231], regulate Inositol 1,4,5-triphosphate (InsP3) 
receptor gating [69, 235], Ryanodine receptor (RyR) channel activity [236, 257] and 
abundance [202]. PS have also been shown to interact with Sarco/endoplasmic reticulum 
calcium-ATPase (SERCA) pump which actively transfers calcium from cytosol into the 
ER [258], and to modulate this function [72, 233]. Capacitative calcium entry (CCE) – 
the process of refilling intracellular calcium stores through plasma membrane channels – 
has been shown to be attenuated in cells expressing FAD PS mutants [246, 259]. 
Moreover, PS2 modulates calcium shuttling between ER and mitochondria [127]. Here 
we aimed to examine the potential role of impaired PS endoproteolysis leading to 
accumulation of PS holoprotein on the ER membrane [260, 261] in the context of 
disrupted ER calcium homeostasis in AD. 
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5.3 Materials and Methods 
 
5.3.1 Cell culture and cell lines 
 
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin while being incubated at 37°C, 5% CO2 and 90% humidity. PS1-
overexpressing and PEN-2 knockdown HEK293 lines were generously provided by Dr. 
H. Steiner. HEK293 cells stably expressing either PS1 wild type or mutant variants, or 
AChRa1 were generated by transfection of HEK293 cells with the respective cDNA 
cloned into pcDNA3.1/Zeo (+) (Invitrogen, Carlsbad, CA, USA) and subsequent 
selection for zeocin (100 µg/ml) resistance. Likewise, RNA interference-mediated PEN-2 
stable knockdown clone was generated by stable transfection of pSUPER/PEN-2-163 and 
pcDNA3.1/Hygro(-) (Invitrogen) into HEK293 cells and subsequent  selection for 
hygromycin (100 μg/ml) resistance [262]. 
 
5.3.2 Calcium imaging 
 
One day prior to the experiment, HEK293 cells were plated in a 96-well collagen coated 
microplate (Greiner BioOne GmbH, Frickenhausen, Germany) at 40,000 cells/well. 
Cytosolic calcium concentration was measured using the Fluo-4 NW kit (Invitrogen 
Corporation, Madison, WI, USA) according to manufacturer’s instructions. Briefly, the 
growth medium was exchanged with a freshly mixed calcium-free assay buffer. The cells 
were incubated at 37°C for 30 minutes, then for an additional 30 minutes at room 
temperature. Fluorimetric calcium measurements were performed utilizing a confocal 
laser-scanning system (Carl Zeiss AG, Jena, Germany) equipped with a climate control 
chamber (EMBL, Heidelberg, Germany). Cells were then imaged using a 40x oil 
immersion objective (Zeiss Plan-Apochromat, Zeiss; 40x NA 1.3). Excitation of the cells 
was performed at 488 nm with an Argon Laser (Zeiss) and the emission was collected 
using band pass filter (500–550 nm). Time-lapse fluorescence images were acquired at 5 s 
interval for Thapsigargin (TP; 1 µM) and 1 s interval for Bradykinin (BK; 300 nM) and 
Carbachol (CCh; 10 µM). Subsequently images were analyzed by defining typically 20-
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30 regions of interest (ROI) for individual cells in each well using the Zeiss LSM 510 
Meta Software. Data analysis was performed using Microsoft EXCEL (Microsoft, Seattle, 
WA, USA), Sigma Plot (SPSS, Chicago, IL, USA) and GraphPad Prism 5.0b (GraphPad 
Software, San Diego, CA, USA). All fluorescence data are expressed as ΔF/F0 = (F – 
F0)/F0, where F is the measured fluorescence signal at any given time and F0 is the 
average fluorescence from the scans preceding stimulation.  
 
If not otherwise stated, values represent mean ± standard error of the mean (SEM). To 
test significance, student's t-test (two tailed) was performed and differences were 
considered statistically significant if p < 0.05. 
 
5.3.3 Treatment with γ-secretase inhibitors 
 
HEK293 cells were grown to 60-70% confluency inside of 10 cm petri dishes. γ-secretase 
inhibitors (all from Calbiochem, Darmstadt, Germany) were added to the growth medium 
and incubated for 24 hours at concentrations which were reported to inhibit the γ-
secretase activity. DAPT, Gamma IV and Gamma XXI were used respectively at 10 µM, 
2.7 µM and 300 nM concentration. Controls were treated in parallel with DMSO vehicle 
instead of inhibitors. 
 
5.3.4 Western blot 
 
HEK293 cells were lysed in “complete lysis-M buffer” with protease inhibitor mix 
(Roche, Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer’s 
instructions. Similarly for human brain material, a small piece from frozen postmortem 
frontal cortex of FAD as well as control cases were cut and homogenized in 
sucrose/hepes buffer with PMSF. Protein concentrations were measured using BCA 
assay. Equal amounts of protein samples were separated in a 10% tris-glycine SDS-
PAGE and transferred to PVDF-membrane (Millipore, Corporation, Bedford, MA, USA). 
For detection of presenilin holoprotein, a rabbit polyclonal antibody against a MBP/PS1-
loop (aa 263-407) fusion protein was used at 1:500 dilution (antibody 5023; a kind gift 
from Dr. H. Steiner [263]). Mouse monoclonal anti-Tubulin (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) was used at 1:1000 dilution for loading control and corresponding 
AP-coupled secondary antibodies (Thermo Scientific, Waltham, MA, USA) at 1:5000 
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dilution. Chemiluminescent reaction was performed with CDP-Star (Roche Molecular 
Biochemicals) and detected with a Chemocam Imager (INTAS Science Imaging 
Instruments GmbH, Göttingen, Germany). Western blot bands were quantified using 
Advanced Image Data Analyzer/2D Densiotometry 3.52 (Raytest GmbH, Straubenhardt, 
Germany). 
 
5.3.5 Human subjects 
 
In total seven frontal cortex samples comprising three FAD-PS1 and one FAD-APP 
mutation carrying patients as well as three control individuals were collected from 
BrainNet Europe. The staging of samples was determined according to Braak & Braak 
during routine postmortem tissue diagnostics by skilled neuropathologists [264]. The use 
of human tissue samples was approved by the institutional review board of the University 
of Munich (BrainNet: Brain Banking Center Munich). 
 
5.4 Results 
 
5.4.1 Effect of PS1 holoprotein overexpression on calcium release from ER 
 
To assess the role of increased PS1 holoprotein levels in the ER calcium homeostasis, we 
used HEK293 cells stably expressing either wild type or several different mutant forms of 
PS1. Typically the endogenous PS1 holoprotein level is relatively low, being on the 
border line of detection [265]. We confirmed remarkable increase in PS1 holoprotein 
expression level by western blotting protein lystes from PS1 stable lines (Figure 5.1a). 
Densitometric analysis indicate 6-7 fold increase in the PS1 full length holoprotein levels 
in all stable clones compared to the wild type HEK293 cells (Figure 5.1b). Likewise the 
PS1-CTF levels were increased in all the clones, except for PS1-DeltaE9 and PS1-D385N 
which both lack the endoproteolytic cleavage site (Figure 5.1a). Overexpression of wild 
type PS1 and to a higher degree various FAD-PS1 mutants led to significantly lowered 
calcium release from ER in comparison to the untransfected controls. The ER calcium 
responses were generated by applying Bradykinin (BK). Application of BK leads to 
liberation of calcium from InsP3-sensitive ER stores. The peak amplitude of the BK-
evoked calcium release alone in wild type PS1 (wtPS1) overexpressing cells was 
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decreased to 71 ±2.2% of control wild type HEK293 cells. All FAD-PS1 mutants further 
lowered the amplitude of BK-evoked calcium release peak size as follows: PS1-DeltaE9 
to 41 ±2.5%, PS1-M146L to 38 ±3.4%, PS1-G384 to 35 ±1.2% and PS1-L166P to 25 
±1.4% of the wild type HEK293 controls (Figure 5.1d). These results were confirmed 
using Thapsigargin (TP) as well. TP is an inhibitor of SERCA pump that blocks calcium 
uptake into ER, causing the diffusion of calcium from ER into the cytosol due to a very 
strong calcium gradient. Following a similar trend, the peak amplitude of TP-evoked 
calcium release in wtPS1 overexpressing cells was reduced to 65 ±1.9 %, in PS1-DeltaE9 
to 29 ±2.1%, in PS1-M146L to 49 ±2.9 %, in PS1-G384 to 35 ±3.2 % and in PS1-L166P 
to 47 ±2.1 % of the wild type HEK293 controls (Figure 5.1f). Importantly, 
overexpression of a mutant form of PS1 being functionally inactive for γ-secretase 
substrate cleavage (PS1-D385N) [266], also resulted in lowered BK-evoked (to 28 ±1.6% 
of wild type) and TP-evoked (to 45 ±3.3 % of wild type) calcium liberation from ER, 
indicating that the observed effects are independent of γ-secretase substrate cleavage 
activity (Figure 5.1d and 5.1f). Moreover, there was no correlation observed between the 
PS1-CTF levels and the attenuated calcium response from ER. PS1-DeltaE9 and PS1-
D385N mutants, which do not undergo endoproteolysis and thus do not generate PS1-
CTF, showed comparable attenuation of ER calcium release as to the rest of FAD-PS1 
mutants which generate approximately proportionate levels of PS1-CTF. Conversely, the 
amplitude of calcium release upon activation of muscarinic receptors with carbachol 
(CCh) was enhanced in FAD-PS1 mutant and PS1-D385N expressing cells (Figure 5.1h). 
On a note, the overexpression of rat nicotinic acetylcholine receptor subunit alpha 1 
(rAChRα1), an unrelated protein which also localizes to the ER did not alter the 
amplitude of BK-evoked calcium release in HEK293 cells (Figure 5.1i). 
 
5.4.2 Effect of γ-secretase inhibitors on calcium release from ER 
 
Next, we investigated the effect of acute γ-secretase inhibition on the ER calcium release. 
After treatment of HEK293 cells for 24 hours with three different γ-secretase inhibitors, 
we measured BK-evoked calcium responses. Treatment with each of the three γ-secretase 
blockers, resulted in significantly lowered BK-evoked calcium response compared to 
vehicle treated controls. The peak amplitude for BK-evoked calcium release for cells 
treated with DAPT, Gamma IV and Gamma XXI were respectively 80 ±2.5%, 58 ±3.3% 
and 75 ±2.8% of that for DMSO treated cells (Figure 5.2a). As another parameter 
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proportional to the amount of released ER calcium, the area under the curve (AUC) of 
BK-evoked calcium responses were calculated. Following a similar trend, the AUC for 
cells treated with DAPT, Gamma IV and Gamma XXI were respectively 61 ±5.1%, 42 
±6.1% and 48 ±6.1% of DMSO-treated cells (Figure 5.2b). Likewise, the amplitude of 
TP- and CCh-evoked calcium responses were attenuated in γ-secretase inhibitor treated 
HEK293 cells (Figure 5.2c and 5.2d). However, treating wtPS1- and PS1-D385N-
overexpressing cells with DAPT did not further potentiate the reduction of BK-evoked 
calcium release (Figure 5.2g and 5.2h). γ-secretase inhibitors were used at concentrations 
which were previously described to inhibit the γ-secretase activity. Based on the literature 
that suggest γ-secretase activity is required for endoproteolysis of PS [267], we postulated 
that the treatment with γ-secretase blockers might inhibit the endoproteolysis of PS1 itself 
as well. Despite the expected faint expression of PS1 holoprotein at endogenous levels 
which could only be detected at longer exposures, we could indeed detect a modest 
increase in the PS1 holoprotein levels upon 24 hours treatment of cells with each of the 
three γ-secretase inhibitors by western blotting (Figure 5.2e). Treatment with DAPT, 
Gamma IV and Gamma XXI respectively led to 48 ±4.1%, 45 ±5.4% and 34 ±4.6% 
increase in detected PS1 holoprotein levels by western blot (Figure 5.2f). 
 
5.4.3 Effect of PEN-2 knockdown on ER calcium release 
 
PEN-2 (Presenilin enhancer 2) is a key regulatory component of the γ-secretase complex 
[268]. PEN-2 is necessary for the proper assembly of active γ-secretase complex and the 
knockdown of PEN-2 is associated with deficiency in PS endoproteolysis leading to 
stabilization and accumulation of PS holoprotein [269, 270]. Here we used RNA 
interference-mediated PEN-2 stable knockdown (PEN-2 KD) in HEK293 cells [262]. The 
cell line was previously characterized by Prokop and colleagues. In this cell line, 
increased PS1 holoprotein levels accompanying the downregulation of PEN-2 was 
demonstrated [262]. The interaction of PS holoprotein with PEN-2 is a key step for PS 
holoprotein to adopt a conformation which allows its endoproteolytic cleavage [262]. The 
PS1 holoprotein increase was confirmed in PEN-2 KD cells (Figure 5.3e). Here we report 
that BK-evoked calcium release is attenuated in PEN-2 knockdown cells relative to wild 
type controls, similar to the observation made in PS1 overexpressing cells. The peak 
amplitude and the area under the curve in PEN-2 KD cells were respectively 42 ±4.9% 
and 55 ±6.6% of those for wild type cells (Figure 5.3a and 5.3b). Similarly, the amplitude 
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of TP- and CCh-evoked calcium responses were also decreased in PEN-2 KD cells 
(Figure 5.3c and 5.3d). 
 
5.4.4 PS1 holoprotein in brains of FAD-PS1 patients 
 
To assess the physiological relevance of the finding that the accumulation of PS 
holoprotein is associated with the attenuated ER calcium release in the context of AD 
pathogenesis, we compared the PS1 holoprotein levels in the postmortem frontal cortices 
of FAD patients relative to non-demented control cases. As expected, the amount of PS1 
holoprotein level in control individuals was relatively low. However we observed on 
average 1.7 fold significant increase in PS1 holoprotein levels in three FAD-PS1 patient 
cases. In contrast, the level of PS1 holoprotein in a FAD-APP patient was comparable to 
the controls (Figure 5.4a and 5.4b). Table 5.1 summarizes the patient data from which the 
samples were collected. 
 
 
5.5 Discussion 
 
Here we report that the conditions causing an enhancement in the amount of PS1 
holoprotein, result in attenuated calcium release from the ER. Only very little is known 
about the exact mechanism of PS holoprotein endoproteolysis. Despite the controversial 
findings, some FAD-PS mutations have been shown to impair the PS endoproteolysis 
leading to accumulation of PS holoprotein primarily on the ER membrane [260, 261]. 
 
Although there exists evidence in favor of FAD-PS mediated “ER calcium overload” 
theory [271], the results presented here and several other studies show that the FAD-PS 
and to a lesser extent wild type PS lead to either attenuated or unchanged ER calcium [69, 
127, 233-235, 259, 272-274]. The reason behind such discrepancies is not completely 
clear. However, in comparing such data one has to critically discriminate between the 
FAD-PS mediated hyperactivity of InsP3R or RyR channels from “ER calcium overload”. 
Those exaggerated calcium responses may simply be a result of enhanced receptor gating 
and/or density [69, 202, 235, 257], increased basal phospholipase C (PLC) activity and 
the consequent overproduction of InsP3 molecule [200, 275], or a combination of those, 
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while being independent from ER calcium content. While previous studies have 
demonstrated the biochemical interaction between PS1 and InsP3R [69], it is established 
that the overxpression of FAD-PS does not alter the abundance of InsP3 receptors [276]. 
Notably, we have also observed augmented carbachol (CCh)-evoked calcium responses in 
FAD-PS1 mutant bearing cells (Figure 5.1g and 5.1h). While calcium release upon 
stimulation with both BK and CCh is associated with G-protein coupled receptor (GPCR) 
activation and InsP3 generation, in spite of sharing the same calcium pools, such 
differential effects between BK- and CCh-evoked calcium responses have been 
previously described in airway smooth muscle and neuroblastoma cells and proposed to 
be regulated by differences in the specific PLC involvement and the expression of 
muscarinic receptors [277, 278]. Furthermore, activation of muscarinic receptors with 
CCh is associated with remarkably higher InsP3 generation as to the activation of 
bradykinin receptors by BK [279]. Therefore it is possible that in CCh-evoked calcium 
release experiments (but not BK-evoked), the contribution of FAD-PS1 mediated 
hyperactivity of InsP3 receptors [69, 235], can mask the lowered ER calcium content. 
Although CCh has been reported to induce calcium release also from RyRs in an InsP3R-
dependent manner [280], due to extremely low expression levels of RyR in HEK293 
cells, the contribution of RyRs in the observed differential effects is rather unlikely [281]. 
Further work is needed to comprehensively elucidate the differences between BK- and 
CCh-evoked calcium responses in the context of FAD-PS expression. 
 
It has been proposed that the holoprotein form of PS can function as passive calcium leak 
channels on the ER membrane allowing the leakage of calcium into the cytoplasm [207, 
228, 256]. Majority of FAD-PS mutations lead to loss of this function, some do not affect 
and others even cause a further gain of this function [40]. Independently from how FAD-
PS mutations modulate the leak activity, it is plausible that the increase in PS holoprotein 
amounts may directly increase the degree of passive calcium leakage from ER to 
cytoplasm. This can explain our observation that conditions increasing the amount of PS1 
holoprotein result in reduced ER calcium. Constant enhanced calcium leakage from ER 
into cytoplasm as a result of PS holoprotein accumulation will in turn affect the calcium 
equilibrium between ER and cytosplasm in which the reached steady state of ER calcium 
level is relatively low. Similar to FAD-PS1 mutants, a loss of function mutant for γ-
secretase activity (PS1-D385N) [266] showed reduced calcium release from ER. This 
observation is in line with another finding showing that γ-secretase cleavage activity is 
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dispensable for the reduction of ER calcium levels, demonstrated using a different γ-
secretase inactive mutant (PS2-D366A) [272]. The PS-mediated attenuation of ER 
calcium release seems to be a specific effect and not caused by ER stress or protein 
overload, since the overexpression of rAChRα1 which also accumulates at the ER [282], 
did not alter the amplitude of BK-evoked calcium release. 
 
We demonstrated that treatment with γ-secretase inhibitors lowers the magnitude of 
calcium release from ER in HEK293 cells. A similar finding has been previously 
described by others as well [283]. However here we propose an alternative explanation 
for this phenomenon which is independent from γ-secretase substrate cleavage activity 
and the suggested functional role for APP intracellular domain (AICD) in calcium 
signaling [283]. We reveal convincing evidence that treatment of HEK293 cells with γ-
secretase blockers results in enhanced PS1 holoprotein levels. This is not very surprising 
given that γ-secretase blockers may also simultaneously inhibit the PS autocatalytic 
activity. The elevated PS1 holoprotein levels would in turn lead to enhanced leakage of 
calcium from ER into cytosol and consequently lowered ER calcium content. Further 
support for this hypothesis comes from the work of Fukumori and colleagues which 
nicely demonstrate that the PS holoprotein endoproteolysis is indeed autolytic [267]. 
Although the detected increase in PS holoprotein was only marginal, in view of extremely 
low levels of endogenously expressed PS holoprotein as well as the tremendous calcium 
gradient between ER and cytosol [26], even such minor but sustained enhancements in 
passive calcium leakage through PS holoprotein may heavily impact the calcium 
equilibrium between ER and cytosol. In both wtPS1 and PS1-D385N overexpressing 
cells, treatment with DAPT did not further reduce the amplitude of BK-evoked calcium 
release. These findings are indeed in line with our hypothesis, since PS1-D385N mutant 
is deficient for endoproteolysis and a marginal increase in PS1 holoprotein levels caused 
by DAPT treatment in wtPS1 cells would be negligible in the presence of constitutive 
PS1 overexpression which accompany abounding PS1 holoprotein levels. In view of 
therapeutic applications, the finding that γ-secretase inhibitors can elevate the PS 
holoprotein levels reflects yet another potential undesirable side-effect associated with the 
use of γ-secretase inhibitors (apart from unspecifically blocking the processing of several 
substrates other than APP) which should be taken into consideration [284]. 
Likewise, we demonstrated that the knockdown of PEN-2 leads to attenuated ER calcium 
release. Prokop and colleagues have shown that the knockdown of PEN-2 is associated 
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with deficiency in PS1 endoproteolysis and accumulation of PS1 holoprotein [262]. Using 
the same cell line, here we show reduced BK-, TP- and CCh-evoked ER calcium 
responses as well. These findings reinforce an inverse correlation between the PS 
holoprotein levels and the amount of calcium release from ER. 
 
In previous studies utilizing AD patient post-mortem brains, the activation of calcium-
dependent proteases and the alterations in the activity and abundance of proteins involved 
in calcium homeostasis were detected [285-287]. In this study, in spite of limited number 
of human postmortem brains from FAD-PS1 cases, we reveal convincing indication that 
the amount of PS1 is upregulated in the brains of patients harboring different FAD-PS1 
mutations. Evidence exists that even in brains of sporadic late-onset AD cases, PS1 
protein and mRNA levels and γ-secretase activity are upregulated [288]. Li et al. have 
postulated that presenilin upregulation may contribute to sporadic AD as a risk factor in 
the context of γ-secretase activity [289]. However, more detailed studies are needed to 
address whether the disturbed calcium homeostasis associated with PS holoprotein 
accumulation plays a role in the pathogenesis of late onset sporadic AD cases too. PS 
holoprotein is quite unstable with a relatively short half-life (~1.5 hours) and a rapid 
turnover [220]. Indeed, FAD-PS1 DeltaE9 mutant was shown to possess relatively higher 
stability and a longer half-life (~40 hours) [220]. Weihl and colleagues have suggested 
that FAD-PS mutations can alter the stability of PS holoprotein in a cell-type and 
differentiation-state dependent manner [290]. Given the emerging roles for PS outside of 
γ-secretase complex, increased stability and/or accumulation of PS holoprotein may have 
direct implications in pathophysiology of AD, particularly through their involvement in 
disruption of ER calcium homeostasis.  
 
The disturbances in ER calcium homeostasis have been observed in both familial and 
sporadic AD cases long preceding the disease hallmarks, i.e. senile plaque and tangle 
pathology [98, 116]. While increasing age is the main risk factor for development of 
sporadic AD, indications suggest that age-dependent alterations in the calcium 
homeostasis may contribute to the pathogenesis of sporadic AD as well [291]. Moreover 
calcium dysregulation plays a key role in synaptic failure and neuronal loss [52]. Notably, 
the latter pathological events correlate best with the stages of dementia [53]. Therefore, 
better understanding the underlying mechanisms responsible for the disruption of ER 
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calcium homeostasis would be valuable in development of therapies targeting calcium 
dyshomeostasis as an early event in AD pathogenesis. 
 
There are controversies in the literature as to how FAD-PS mutations alter ER calcium 
handling. These variations were mainly attributed to differences in methodologies used, 
different cells types and mutations. However based on the results here, we suggest that in 
the experimental setups where either wild type or mutant PS forms are overexpressed, 
possible differences in the PS expression levels may potentially give rise to the 
inconsistencies between independent studies. This point becomes even more critical 
taking into account that the expression level of PS holoprotein is quite low under 
physiological conditions. Given the fact that only a fraction of PS can incorporate into γ-
secretase complex [292], constitutive overexpression might be suitable for studying the 
effect of PS mutations on γ-secretase activity. However when FAD-PS-dependent 
alterations in the ER calcium homeostasis are investigated, overexpression of PS might 
not fully resemble their role in pathophysiological circumstances. Therefore the use of 
patient derived FAD-PS cells (e.g. fibroblasts, lymphocytes, etc) which express PS 
holoprotein at endogenous levels may be more appropriate. On the other hand, since 
FAD-PS mutations alter the stability of PS holoprotein in a cell-type and differentiation-
state dependent manner [290], calcium homeostasis in periphery might not exactly 
correspond to the FAD-PS-mediated disruption of calcium homeostasis in the brain. 
Despite the mentioned drawbacks associated with the use of overexpression and 
secondary cell models, HEK293 cells were suitable for the purpose of this study. 
Regulation of calcium homeostasis in neurons is a very complex mechanism which is 
tightly controlled by the functions of multiple molecular elements. The existence of 
compensatory mechanisms which by masking studied effect can efficiently restore 
balanced calcium homeostasis makes the manipulation of calcium signaling in neurons 
for studying cause-effect relationships rather challenging. By contrast, in simpler cell 
models (e.g. HEK293 cells), in shortage of such efficient compensatory mechanisms, 
directly assessing the effect of PS1 holoprotein accumulation on ER calcium homeostasis 
was more readily possible. 
 
Taken together our results reinforce the notion that the accumulation of full length forms 
of PS (as a result of e.g. impaired PS autoendoproteolysis) result in reduced ER calcium 
content. Therefore future studies are necessary to examine whether the adverse FAD-PS-
48 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
mediated effects on the functions of several ER calcium handling elements, including 
described loss of PS calcium leak channel activity [228], enhanced InsP3 [69, 235], and 
RyR channel activity [236, 257] and abundance [202, 230] could be secondary 
mechanisms to compensate for the PS holoprotein-associated attenuation of ER calcium 
load.  
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Table 5.1: Human frontal cortex postmortem brain materials examined for PS1 holoprotein levels 
 
Sample 
Number 
Diagnosis Age 
(years) 
Sex Postmortem 
interval (hours) 
Braak&Braak 
Stage 
RZ145 Control 85 F 20 I 
RZ340 Control 54 M 9.5 0 
RZ342 Control 83 F 22 II 
RZ179 PS1 Leu286Val 57 M 44 VI 
RZ265 PS1 Leu174Arg 57 F 34 VI 
RZ272 PS1 Ile143Thr 39 M 7 VI 
RZ421 APP Thr714Ile 49 M 48 VI 
50 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
 
 
 
Figure 5.1. Altered calcium release from ER in PS1-overexpressing HEK293 cells 
(a) Representative immunoblot indicating the expression of PS1 in HEK293 cells. The expression of PS1-FL 
holoprotein and PS1-CTF protein were analyzed using MBP/PS1-loop (aa 263-407) antibody on western blot 
using the protein lystes from wild type cells, cells stably overexpressing wild type PS1, several FAD-PS1 
mutants and a γ-secretase inactive mutant (PS1-D385N). 5 µg of protein lysate was loaded into each lane 
on the gel. 
(b) Densitometric quantification of PS1-FL band intensity normalized to loading control Tubulin (n=3). 
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(c) Representative traces of BK-evoked, (e) TP-evoked and (g) CCh-evoked calcium releases for wild type 
HEK293 cells, HEK293 cells stably overexpressing wild type or mutant PS1 and the corresponding calcium 
images for the time points indicated with arrows displayed in pseudocolors. 
 
(d) Average peak amplitude of BK-evoked and (f) TP-evoked calcium release from ER are significantly 
reduced in cells stably expressing wild type PS1 versus wild type HEK293 cells. Furthermore BK- and TP-
evoked calcium responses are significantly attenuated in cells overexpressing mutants form of PS1 in 
comparison to both wild type PS1-overexpressing and plain wild type HEK293 cells. 
(h) Average peak amplitude of Carbachol (CCh)-evoked calcium release from ER is significantly amplified in 
HEK293 cells stably expressing mutant forms of PS1 relative to cell stably expressing wild type PS1 and 
plain wild type HEK293 cells (*** P<0.001). 
(i) Average peak amplitude of BK-evoked calcium release from ER is unchanged in HEK293 cells stably 
overexpressing rAChRα1 relative to wild type HEK293 cells. 
(n.s.: non-significant) 
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Figure 5.2. Attenuated calcium release from ER after treatment of HEK293 cells with γ-secretase 
inhibitors 
(a) Average peak amplitude and (b) the area under the curve (AUC) of BK-evoked calcium release and (c) 
the average peak amplitude of TP- and (d) CCh-evoked calcium release from ER are significantly reduced in 
HEK293 cells treated with γ-secretase inhibitors for 24 hours. DAPT, Gamma IV and Gamma XXI were used 
respectively at 10 µM, 2.7 µM and 300 nM concentration (* P < 0.05, ** P<0.01 and *** P<0.001). 
(e) Increase in PS1-FL (holoprotein) levels were detected by western blot in HEK293 cells. (f) Densitometric 
quantification of PS1-FL band intensities normalized to loading control Tubulin in (e) (n=3). 10 µg of protein 
lysate was loaded into each lane on the gel (* P<0.05 and ** P<0.01). 
Average peak amplitude of BK-evoked calcium response in (g) wild type PS1- and (h) PS1-D385N-
overexpressing HEK293 cells is unchanged after treatment with DAPT for 24 hours. 
(n.s.: non-significant) 
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Figure 5.3. Attenuated calcium release from ER in PEN-2 KD cells 
(a) Average peak amplitude and (b) the area under the curve (AUC) of BK-evoked calcium release and (c) 
the average peak amplitude of TP- and (d) CCh-evoked calcium release from ER are significantly reduced in 
PEN-2 KD cells compared to wild type HEK293 cells (** P<0.01). 
(e) Increased PS1-FL (holoprotein) levels detected by western blot in PEN-2 KD cells. 10 µg of protein lysate 
was loaded into each lane. 
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Figure 5.4: Elevation of PS1 holoprotein levels in frontal cortices of FAD-PS1 patients 
(a) Significant increase in PS1-FL (holoprotein) levels was detected by western blot in postmortem frontal 
cortex samples from FAD-PS1 cases (RZ179, RZ265 and RZ272), but not in a FAD-APP case (RZ421), 
compared to control cases (RZ145, RZ340 and RZ342). 15 µg of brain homogenate was loaded in each lane 
on the gel (** P<0.01). 
(b) Densitometric quantification of PS1-FL band intensities normalized to loading control Tubulin in (a).  
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6.1 Abstract 
 
Disrupted intracellular calcium homeostasis occurs early in the cascade of events leading 
to Alzheimer’s disease (AD) pathology. Particularly familial AD mutations linked to 
Presenilins result in exaggerated agonist-evoked calcium release from endoplasmic 
reticulum (ER). Here we report the development of a fully automated high-throughput 
calcium imaging assay utilizing a genetically-encoded FRET-based calcium indicator at 
single cell resolution for compound screening. The established high-throughput screening 
assay offers several advantages over conventional high-throughput calcium imaging 
technologies. We employed this assay for drug discovery in AD by screening compound 
libraries consisting of over 20,000 small molecules followed by structure-activity-
relationship analysis. This led to the identification of Bepridil, a calcium channel 
antagonist drug in addition to four further lead structures capable of normalizing the 
potentiated FAD-PS1-induced calcium release from ER. We detected increased AMPK 
activity upon treatment of cells with Bepridil in a dose-dependent manner. AMPK 
activation by Bepridil is most likely a calcium-dependent phenomenon, since CaMKK 
inhibition by STO-609 abolishes the Bepridil-induced AMPK activation. Interestingly, it 
has recently been reported that Bepridil can reduce Aβ production by lowering BACE1 
activity. Indeed, we also detected lowered Aβ, increased sAPPα and decreased sAPPβ 
fragment levels upon Bepridil treatment. Therefore based on the results here, we propose 
a novel calcium-dependent mode of action for Bepridil which through activation of 
AMPK can shift the balance of downstream APP processing from amyloidogenic β-
cleavage towards non-amyloidogenic α-cleavage. 
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6.2 Introduction 
 
Alzheimer's disease (AD) is the most common form of dementia [293]. Major 
breakthroughs in understanding the underlying pathomechanisms of AD within the last 
few decades have not yet yielded effective disease-modifying therapies. The major 
hallmarks of AD are the accumulation of intracellular neurofibrillary tangles of 
hyperphosphorylated tau protein and extracellular plaques of β-amyloid (Aβ) protein in 
brain [293]. Current AD drug development mainly focuses on targeting these two major 
pathological features. However, there is evidence that long before the manifestation of 
those hallmarks and cognitive deficits in AD, the neuronal calcium homeostasis is 
disturbed as a result of aging or due to missense mutations in Presenilin genes – the most 
common cause of early onset familial AD (FAD) [25, 40-42, 52, 255]. Long-term 
disruption of calcium homeostasis has been shown to both trigger and accelerate Aβ and 
tangle pathologies [49, 50, 294-296]. Moreover, calcium dysregulation as an early event 
in AD progression plays a key role in synaptic failure and neuron loss [53, 297]. Notably, 
the latter irreversible pathological events correlate best with the stages of dementia [53, 
298]. Calcium alterations in peripheral tissues have been even proposed as diagnostic 
markers for mild AD [47]. Interestingly, Memantine, one of the only few approved drugs 
for treatment of moderate-to-severe AD patients, is an NMDA receptor antagonist which 
by inhibition of sustained calcium influx leads to stabilization of intracellular calcium 
homeostasis [37]. Therefore, restoring disrupted calcium homeostasis as an early event 
leading to cellular dysfunction may open novel avenues to more efficient treatment of AD 
patients. Hence, we examined the possibility of stabilizing intracellular store calcium 
homeostasis, particularly in the endoplasmic reticulum (ER), as an innovative target for 
AD drug discovery. To that end, we developed a high-throughput compound screening 
assay and screened over 20,000 small molecules which led to the identification of lead 
structures which can stabilize the familial Alzheimer’s disease linked mutant Presenilin 1 
(FAD-PS1) mediated disruption of ER calcium homeostasis.  
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6.3 Materials and Methods 
 
6.3.1 Cell culture and cell lines 
 
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin while being incubated at 37°C, 5% CO2 and 90% humidity. All 
stable PS1 lines (generously provided by Dr. S. Lammich) were carrying PS1 variants 
that were cloned into pcDNA3.1/Zeo(+) and selected via Zeocin antibiotic resistance. The 
PS1 lines were then stably transfected with YC3.6/pcDNA3 construct (kindly provided by 
Dr. A. Miyawaki) and respectively isolated by G418 antibiotic resistance leading to 
generation of double stable lines. The APP- , C99- and APPsw/PS1-M146L-
overexpressing HEK293 lines were kindly provided by Dr. S. Lichtenthaler and Dr. H. 
Steiner and cultured as it has been previously described [299, 300]. 
 
6.3.2 Compound Library 
 
DIVERSetTM 1 and 2 libraries (ChemBridge Corp., San Diego, CA, USA), each 
containing a diverse collection of 10,000 hand-synthesized small molecules (in total 
20,000 compounds) as well as a medium size ion channel ligand library (Enzo Life 
Sciences GmbH, Lörrach, Germany) comprising 72 further structures were used for high-
throughput compound screening. Compounds fulfilled the “Lipinski´s rule of 5”, 
indicating their high druglikeness potential [301]. 
 
6.3.3 High-throughput calcium imaging assay and automated image analysis 
 
For the primary screen, HEK293 cells stably expressing PS1-M146L and Yellow 
Cameleon 3.6. (YC3.6) were seeded at 13,000 cells/well in 40 µl of growth medium on 
collagen-coated 384-well CellCarrier plates (PerkinElmer, Rodgau, Germany). After 6 h, 
using an automated pipetting robot (Bravo®; Agilent Technologies, Santa Clara, CA, 
USA), library compounds were added to each well at the final concentration of 10 µM in 
1% DMSO, each in 4 replicates. All plates contained Thapsigargin (TP; 1 µM; 
Calbiochem, Darmstadt, Germany), Cyclopiazonic acid (CPA; 20 µM; Calbiochem) and 
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3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester (TMB-8; 50 µM; Sigma-
Aldrich, Taufkirchen, Germany) as positive controls, as well as untreated and DMSO 
vehicle-treated wells. After 24 h using the pipetting robot, DRAQ5 (Biostatus Ltd, 
Leicestershire, UK), a far-red fluorescent nuclear dye, was added to each well at the final 
concentration of 500 nM. After 2 h, plates were measured for Carbachol (CCh)-induced 
calcium release using the Opera® high-throughput confocal imaging platform 
(PerkinElmer Cellular Technologies GmbH, Hamburg, Germany). Throughout imaging 
of the entire plate, 37°C temperature, 5% CO2 and 90% humidity was maintained in the 
plate chamber. Using a 442 nm laser, YC3.6 was excited and its CFP and YFP emissions 
were separated respectively using 483/35 nm and 540/75 nm filters. Additionally, using a 
640 nm laser DRAQ5 dye was excited and its emission was collected by 690/50 nm filter 
in order to locate the nuclei. Imaging was performed with a 20x water immersion 
autofocus objective. The duration of the entire time-lapse calcium imaging for each well 
was 23.5 s. This was achieved by imaging at 2.5 s interval resolution prior to dispensing 
CCh (for 5 s) to monitor the basal calcium levels. Next, the CCh-induced calcium rise and 
decay was monitored for 18.5 s post dispensing. Imaging was performed first at 1 s 
interval resolution immediately after dispensing (for 5 s) and subsequently at 2.5 s 
interval resolution (for 12.5 s). During dispensing, 10 µl of CCh (Calbiochem) diluted in 
HBSS (10 µM) was injected to each well concurrent with calcium imaging by an 
automated dispensing unit which is part of the Opera® platform. Imaging was performed 
sequentially for all 384 wells. Using Acapella® software (PerkinElmer Cellular 
Technologies GmbH), an automated image analysis tool was developed to translate 
fluorescent signals to numerical values. Here, DRAQ5 and YC3.6 signals were used 
respectively to detect single cell nuclei and single cell boundaries over the entire course 
of time-lapse calcium imaging. After assigning each cell to its segmented nuclei and 
excluding the cells positioned at the edges of the imaging frames, calcium transients for 
every cell were monitored by plotting the kinetics of YFP/CFP versus time and 
normalizing the signals using the equation, ΔF/F0 = (F – F0)/ F0, where F is the measured 
fluorescence signal at any given time and F0 is the average fluorescence signal of the time 
points preceding CCh application. The peak amplitude of calcium rise upon CCh 
injection was the output of automated image analysis at single cell level. Non-responsive 
cells to CCh were excluded from analysis by setting an arbitrarily defined threshold. The 
average peak amplitude of all responsive cells in each well was calculated as the final 
readout in this assay. 
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6.3.4 Data mining 
 
Data mining, clustering and identification of the lead structures were performed with the 
Benchware DataMiner software (Tripos, St. Louis, MO, USA). 
 
6.3.5 Cytotoxcity assay 
 
The cytotoxicity of the compounds was assessed in vitro using the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay kit (Roche 
Diagnostics GmbH, Mannheim, Germany) according to manufacturer’s instructions and 
previously described protocols [302]. In brief, HEK293 cells were cultured at a density of 
35,000 cells/well in 96-well cell culture plates (Nunc GmbH, Langenselbold, Germany). 
On the next day, compounds (10 µM) were added to separate wells in triplicates. Cells 
viability was analyzed after 24 h incubation with the compounds. For this purpose, 10 µl 
of MTT (5 mg/ml in PBS) was pipetted to each well, followed by 4 h incubation at 37°C. 
The formed formazan crystals were dissolved by adding 100 µl of 10% SDS (dissolved in 
0.01 M HCl) to each well and the plates were shaken vigorously to ensure complete 
solubilization. The absorbance was measured at 560 nm using a microtiter-plate reader 
(FLUOstar Optima, BMG Labtech GmbH, Ortenberg, Germany). Values are presented as 
percentage of viable cells. 
 
6.3.6 Aβ measurements 
 
Levels of three different Aβ species (Aβ38, Aβ40 and Aβ42) were measured using 
sandwich ELISA. Pools of HEK293 cells stably transfected with APPsw/PS1-M146L or 
APP were used to study the effect of compounds on Aβ generation. According to Page et. 
al. [300], cells were seeded at a density of 200,000 cells/well in collagen/poly-L-lysine 
(PLL)-coated 24-well plates and incubated for 24 h in growth medium. Next, the medium 
was exchanged with 500 µl of fresh medium containing either Bepridil (3 - 30 µM, 
Sigma-Aldrich), STO-609 (50 µM, Calbiochem) or the positive controls DAPT (10 µM, 
Calbiochem) and Sulindac sulfide (50 µM, Sigma-Aldrich) or vehicle. After 16 h 
conditioned medium was collected and the levels of secreted Aβ38, Aβ40 and Aβ42 
fragments were quantified using “Human (6E10) Abeta 3-Plex” sandwich ELISA 
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immunoassay kit (Meso Scale Discovery, Rockville, MD, USA) according to the 
instructions of the manufacturer. In brief, 150 µl of blocker reagent was added to each 
well of the ELISA plate and incubated for 1 h at room temperature, followed by 3x 
washing using TRIS wash buffer. Next, 25 µl of detection antibody was added to each 
well. At appropriate dilution, each of the samples or calibration standards were added to 
separate wells of ELISA plate and incubated for 2 h at room temperature, followed by 3x 
washing using TRIS wash buffer. Finally 150 µl of read buffer was added to the wells. 
The light emission after electrochemical stimulation was measured using Sector Imager 
2400 reader (Meso Scale Discovery). Based on the values generated with calibration 
standards, corresponding concentrations of Aβ species were calculated using the Meso 
Scale Discovery Workbench software. All measurements were performed in four 
replicates. 
 
6.3.7 sAPPα and sAPPβ measurements 
 
Levels of sAPPα and sAPPβ fragments were measured using sandwich ELISA. HEK293 
cells stably expressing APP or APPsw/PS1-M146L were seeded at a density of 200,000 
cells/well in collagen/poly-L-lysine (PLL)-coated 24-well plates and incubated for 24 h in 
growth medium. Next, the medium was exchanged with 500 µl of fresh medium 
containing either compounds or vehicle. After 16 h conditioned medium was collected 
and the levels of secreted sAPPα and sAPPβ fragments were quantified using 
sAPPα/sAPPβ sandwich ELISA immunoassay kit (Meso Scale Discovery) according to 
the instructions of the manufacturer. In brief, 150 µl of blocker reagent was added to each 
well of the ELISA plate and incubated for 1 h at room temperature, followed by 3x 
washing using TRIS wash buffer. Next, 25 µl of samples or calibration standards were 
added to separate wells of ELISA plate and incubated for 1 h at room temperature, 
followed by 3x washing using TRIS wash buffer. Then 25 µl of detection antibody was 
added to each well and incubated for 1 h at room temperature, followed by 3x washing 
using TRIS wash buffer. Finally, 150 µl of read buffer was added to the wells. The light 
emission after electrochemical stimulation was measured using Sector Imager 2400 
reader (Meso Scale Discovery). Based on the values generated with calibration standards, 
corresponding concentrations of sAPPα and sAPPβ were calculated using the Meso Scale 
Discovery Workbench software. All measurements we performed in four replicates. 
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6.3.8 AMPK activity assay 
 
The AMP-activated protein kinase (AMPK) activity was determined by means of 
measuring pThr172AMPK levels using sandwich ELISA immunoassay (Invitrogen Corp., 
Camarillo, CA, USA). HEK293 cells were seeded at a density of 200,000 cells/well on 
collagen/poly-L-lysine (PLL)-coated 24-well plates and incubated for 24 h in growth 
medium. Next, medium was exchanged with 500 µl of fresh medium containing Bepridil 
(0.1 - 50 µM; Sigma-Aldrich) and/or STO-609 (50 µM; Calbiochem), or DMSO vehicle. 
After 16 h medium was removed and wells were washed 3x with ice cold PBS. Next the 
cells were lysed in 120 µl of ice cold lysis buffer and the lysates were used to quantify the 
AMPK activity level using the method adapted from Moreno-Navarrete et al. [303]. The 
assay was performed according to the manufacturer’s instructions. In brief, to each well 
of the ELISA plate 100 µl of the lysates or calibration standards was added and incubated 
for 2 h at room temperature, followed by 4x washing using assay wash buffer. Next 100 
µl of detection antibody was added to each well and incubated for 1 h at room 
temperature, followed by 4x washing using assay wash buffer. Then 100 µl of HRP anti-
rabbit antibody was added to the wells and incubated for 30 min at room temperature, 
followed by 4x washing using the assay wash buffer. Finally 100 µl of stabilized 
chromagen was added to the wells and the reaction was stopped after 30 min by adding 
“stop” solution to the wells. The absorbance was measured at 450 nm using a microtiter-
plate reader (FLUOstar Optima, BMG Labtech GmbH). pAMPK levels were calculated 
based on the absorptions of the standards and their calibration curve. All the 
measurements were performed in duplicates. 
 
6.3.9 Statistical data analysis 
 
GraphPad Prism 5.0b (GraphPad Software, San Diego, CA, USA) was used for statistical 
analysis of the data. Values represent mean ± standard deviation. To test significance, 
two-tailed student's t-test was performed and differences were considered statistically 
significant if p < 0.05. The Z’-factors were computed according to Zhang et al. [304], 
where TP was used as a positive and DMSO as a negative control. 
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6.4 Results 
 
6.4.1 FAD-PS1 mutations enhance the amplitude of CCh-induced calcium release 
and the number of responsive cells 
 
Mutations in presenilins (PS1 and PS2) account for the vast majority of early onset 
familial Alzheimer’s disease (FAD) cases. These mutations result in enhancement of 
inositol 1,4,5-trisphosphate (IP3) receptor sensitivity [69, 235]. As expected, the peak size 
of CCh-evoked calcium release in all FAD-PS1 lines was approximately 3 folds higher 
than in wild type PS1 line (Figure 6.1a). Moreover, a remarkable increase in the number 
of CCh-responsive cells was consistently detected in all FAD-PS1 lines. In wild type PS1 
line, only 29% of the cell population was CCh-responsive, whereas in all FAD-PS1 
mutant lines, over 95% of the cell population responded to CCh (10 µM) (Figure 6.1b). 
Taken together, FAD-PS1 expression enhances the number of responsive cells to CCh 
and amplifies the peak size of CCh-evoked calcium response. Likewise, the expression of 
a γ-secretase-deficient mutant form of PS1 (PS1-D385N) results in increased 
responsiveness to CCh and augmented calcium release from ER upon CCh stimulation 
(Figure 6.1a and 6.1b). In the next set of experiments, the augmented CCh-evoked 
calcium release in FAD-PS1 expressing cells was used as the target to screen for 
compounds that can restore exaggerated calcium release to physiological levels. 
 
6.4.2 High-throughput compound screening assay enables the discovery novel lead 
structures 
 
We addressed intracellular store calcium dyshomeostasis as an innovative target for drug 
discovery with a novel FRET single-cell-based calcium imaging technique in a fully 
automated high-throughput kinetic assay on the Opera® system (PerkinElmer) for 
compound screening.  
 
Yellow Cameleon 3.6 (YC3.6), a superior genetically-encoded FRET-based calcium 
probe with expanded dynamic range and fast kinetics [212], was introduced to HEK293 
cells as a tool to monitor both the basal calcium concentrations and the released calcium 
from ER in real-time by confocal imaging. YC3.6 is composed of CFP and YFP linked 
64 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
via calmodulin (CaM) and a CaM-binding peptide (M13). Upon calcium binding it 
undergoes a conformational change and thereby FRET efficiency increases (Figure 6.2a) 
[212]. The assay readout was the peak size of potentiated inositol-1,4,5-trisphosphate 
receptor (IP3R)-evoked calcium release from ER in HEK293 cells carrying a disease-
causing mutated form of PS1 (PS1-M146L). Agonist-induced IP3 production by CCh 
results in calcium release from ER (Figure 6.2b). As presented here and reported by 
others as well [223], FAD-PS mutations mediate exaggerated CCh-induced calcium 
release compared to wild type PS1 expressing cells (Figures 6.1a and 6.2c). Notably, 
CCh-evoked calcium responses were evaluated at several different CCh concentrations. 
However, the most remarkable difference in the peak size of CCh-evoked calcium release 
in FAD-PS1 versus wild type PS1 lines was detected at 10 µM CCh (data not shown). 
 
As illustrated in figure 6.2d, HEK293 cells stably coexpressing FAD-linked PS1-M146L 
mutation and YC3.6 were seeded on 384-well optical bottom plates. After 6 h, 
compounds from the library plates were added to separate wells using a pipetting robot. 
After 24 h incubation with compounds, DRAQ5 nuclear marker was added to the wells. 
After 2 h, time-lapse calcium imaging was performed and CCh-induced calcium release 
was monitored sequentially for each well with the use of YC3.6 calcium indicator. In 
addition, the signal of DRAQ5 dye was also collected throughout the entire course of 
time-lapse imaging. Using “Acapella” software (PerkinElmer), an automated image 
analysis tool was developed to convert fluorescent signals in large number of cell 
populations to numerical values. To that end, DRAQ5 signal was used to detect all nuclei 
in each frame and the YC3.6 signal was used to assign the detected single cell boundaries 
to their corresponding segmented nuclei over the entire course of time-lapse calcium 
imaging. On average, approximately 150-200 cells were detected for each well. For every 
detected cell, calcium transients were measured by calculating YFP/CFP over the course 
of imaging. The peak amplitude size of the calcium rise upon CCh injection was the 
output of automated analysis at single cell level. The ability to simultaneously monitor 
calcium transients for all individual cells of a well enabled us to filter out CCh-non-
responsive cells from the analysis by setting an arbitrarily defined threshold. The average 
peak amplitude of all responsive cells in a well was calculated as the final output of the 
image analysis tool. 
 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 65 
The performance of the high-throughput compound screening assay remained very robust 
throughout screening of 201 plates (Z’-factor > 0.8). Z’-factors for ten randomly selected 
screened plates are presented in figure 6.2e. The average Z’-factor for those ten plates 
was determined to be 0.806 ±0.029, reflecting a robust assay for high-throughput 
screening (HTS). 
 
After filtering the autofluorescent and highly toxic compounds, 53 active small molecule 
hits were identified from the primary screen (Figure 6.3). A compound was regarded as 
active if the peak size of calcium release in cells treated with that compound was 90% or 
smaller than the peak size of DMSO-treated controls on the same plate. To each library 
compound a numerical value typically <1.0 was assigned indicating a measure for its 
efficacy, calculated by dividing the peak size of calcium release in cells treated with that 
given compound to the peak size of DMSO-treated controls on the same plate. Hereafter, 
we refer to this value as “normalized ER calcium response”. In figure 6.3, the list of all 
hits from the primary screen including their chemical structures and corresponding 
normalized ER calcium response values is presented. 
 
The activity of the entire set of 53 hits in terms of reducing the peak size of CCh-evoked 
calcium release was validated and confirmed in PS1-M146L line again (Figure 6.4a). 
Moreover, all primary hits were capable to attenuate the CCh-evoked calcium release in 
three other cell lines expressing either different FAD-PS1 mutations (PS1-DeltaE9 and 
PS1-C92S) or a γ-secretase-deficient PS1 mutant (PS1-D385N) (Figures 6.4e-6.4g). This 
indicates that the activity of the identified hits in normalizing the exaggerated FAD-PS1-
mediated CCh-evoked calcium release is indeed not only specific to the FAD-PS1 
mutation used in the primary screen, but present across other examined PS1 mutations as 
well.  
 
53 structures identified from the primary screen were classified into different categories 
based on their efficacy in attenuating the peak size of the CCh-evoked calcium release 
(Figure 6.4c and 6.4d). These categories are separated according to the corresponding 
value of normalized ER calcium response, presented as percentages relative to the peak 
size of DMSO-treated control. 
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Next, we performed an MTT assay in order to assess the cytotoxicity of the entire set of 
53 hits generated from the primary screen. Majority of identified active compounds 
showed no toxicity and HEK293 cells treated with 10 µM of the compounds for 24 h 
remained viable (Figure 6.4h). Treatment with only 5 compounds, 3 of which belonging 
to Thiazolidine lead structure, resulted in 30-40% reduction in cellular viability. 
 
After performing structure-activity-relationship (SAR) studies with the entire collection 
of library compounds using “Benchware DataMiner” software (Tripos), 4 different lead 
structures were identified. Those structures belonged to following compound classes: 
Thiazolidine, Phenothiazine, Imidazole and Benzhydrilpiperidinamin (Figure 6.4b, 6.S1, 
6.S2, 6.S3 and 6.S4). To that end, first the library consisting of 20,000 compounds was 
imported to the data mining software and active compounds (normalized ER calcium 
response < 0.9) were selected. Using the “OptiSim” algorithm groups of similar 
compounds, called clusters, were identified. Subsequently inactive compounds were 
added to the existing clusters. Then the clusters were combined according to their 
structures in order to reduce their number. Then a SAR map of the clusters was generated 
and clusters with more than 50% active compounds were represented as stars and clusters 
with less than 50% active compounds as rectangles. In addition, all clusters that have 
more than 4 active compounds were colored in blue and otherwise in red. The sizes of the 
symbols correlate directly with the number of compounds in each cluster (Figure 6.4b). 
 
6.4.3 Effect of Bepridil on CCh-evoked calcium release from ER 
 
In addition to 4 discovered lead structures, the HTS led to the identification of Bepridil, a 
calcium antagonist drug which was previously shown to be beneficial against AD through 
simultaneously targeting β- and γ-secretases [299]. In view of the detected Bepridil 
activity in dampening the exaggerated FAD-PS1-mediated calcium release and the 
promising indications linking it to lowered Aβ generation, we synthesized 15 derivative 
structures in an attempt to generate Bepridil-analogous molecules with improved efficacy 
(Figure 6.S5). The derivatisation strategy aimed to explore the contribution of different 
fragments to the potency and efficacy by removal of these moieties (BSc4040 and 
BSc4209). We varied the lipophilicity (BSc4040 and BSc3946), solubility, basicity 
(BSc4049) and membrane permeation by introduction of an ammonium salt (BSc3947) or 
sulfonic acid (BSc3963) and carboxylic acids (BSc3964 and BSc4065). Using the same 
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HTS assay employed in primary screening, we measured dose-dependent effects for 
Bepridil and its synthesized derivatives at 30, 10, 3, 1, 0.3 and 0.1 µM (Figure 6.5). The 
chemical modifications in the structure of Bepridil did not further improve the efficacy in 
attenuating the CCh-evoked calcium release (Figure 6.5). Therefore in the following 
experiments the original Bepridil structure identified from the primary screen was further 
characterized to determine its mode of action. Notably, Bepridil had no effect on the peak 
size of CCh-evoked calcium release in wildtype PS1 expressing cells (Figure 6.S6). 
 
6.4.4 Effect of Bepridil on APP processing and Aβ generation 
 
Mitterreiter and colleagues have shown that Bepridil treatment decreases the formation of 
Aβ by shifting the balance of APP processing from amyloidogenic β-cleavage towards 
non-amyloidogenic α-cleavage [299]. In line with their observation, we also detected 
reductions in the level of secreted Aβ38, Aβ40 and Aβ42 peptides upon 16 h exposure of 
APPsw/PS1-M146L-overexpressing HEK293 cells with Bepridil at 30 µM (Figure 6.6a). 
Likewise, in APP-overexpressing HEK293 cells we detected lower Aβ38, Aβ40 and 
Aβ42 generation after Bepridil treatment (30 µM) for 16 h (Figure 6.S7a). However, upon 
Bepridil treatment at lower concentrations (10 µM and 3 µM), we detected reduced Aβ38 
and Aβ40, but increased Aβ42 levels (Figure 6.S7a). Treatment of C99-overexpressing 
HEK293 cells with Bepridil (30 µM) also leads to decreased Aβ38 and Aβ40 and 
increased Aβ42 levels, suggesting an inverse γ-secretase modulator (iGSM), as previously 
also described [299] (Figure 6.S7b). The reduction in the Aβ amounts was accompanied 
by an increase in sAPPα and a decrease in sAPPβ secreted fragments in a dose-dependent 
manner, indicating that Bepridil treatment indeed enhances the activity of α-secretase and 
inhibits the activity of β-secretase in two different cell lines (Figure 6.6b and 6.S7c). 
Furthermore, we also tested the effect the other active compounds derived from the 
primary calcium screen on Aβ peptide production. Depending on the compound tested, 
we detected increased, decreased or unchanged Aβ levels upon 16 h exposure of 
APPsw/PS1-M146L HEK293 cells with the compounds (Figure 6.S8). 
 
6.4.5 Effect of Bepridil on AMPK activity 
 
There exists evidence that the activation of AMP-activated protein kinase (AMPK) is 
partially calcium-dependent and modulating its activity affects APP processing [305]. In 
68 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
order to assess the effect of Bepridil on AMPK activity, we measured phosphorylated 
AMPK (pAMPK) levels. pAMPK is the activated form of AMPK and its phosphorylation 
is directly associated with AMPK activity [305]. We detected increased pAMPK levels 
upon 16 h treatment of HEK293 cells with Bepridil in a dose-dependent manner (Figure 
6.6c). Calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ) is an upstream 
kinase responsible for calcium-dependent activation of AMPK [306, 307]. In order to 
examine whether AMPK activation by Bepridil is a CaMKKβ-dependent phenomenon, 
we used STO-609, a specific CaMKK inhibitor [308]. Indeed, cotreatment of HEK293 
cells with STO-609 and Bepridil partially abolished the Bepridil-dependent AMPK 
activation (Figure 6.6d). Moreover, CaMKK inhibition with STO-609 also reversed the 
Bepridil-mediated increase in sAPPα, but not the decrease in sAPPβ (Figure 6.S7d).  
 
6.5 Discussion 
 
Here we describe the development and implementation of a high-throughput compound 
screening assay targeting ER calcium dysregulation as an innovative approach for AD 
drug discovery. As opposed to the majority of AD drug discovery strategies that target 
late stage disease hallmarks, this approach targets one of the earliest and most upstream 
events in AD progression before the appearance of characteristic AD pathological 
features. Targeting late events in the course of the AD, during which the disease has 
likely reached an irreversible stage, could be one of the reasons for the consistent recent 
failure of disease-modifying AD drug candidates targeting Aβ and tangle pathologies in 
late clinical phases [14]. To our knowledge, the possibility of targeting disrupted ER store 
calcium homeostasis as an upstream event in disease pathogenesis has never been 
examined in AD drug discovery in the past.  
 
The HTS assay developed offers several advantages compared to current calcium 
measurement screening technologies. Firstly, the use of genetically-encoded calcium 
sensors as opposed to conventional synthetic organic dyes allows monitoring long-term 
intracellular calcium dynamics without the drawbacks caused by dye toxicity, loading, 
washing and leakage. In addition to being able to follow long-term calcium 
concentrations, short-term calcium imaging can be performed at multiple time points, 
which could even be spread over several days. Since the Opera® HTS platform is 
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equipped with an environmental control chamber, excellent long-term cell viability 
conditions are ensured by maintaining regulated temperature, humidity and CO2. 
Secondly, the developed HTS assay allows performing rapid automated dispensing of 
reagent jets to individual wells during calcium measurements with no time lag between 
dispensing and imaging. The latter is ideal for kinetic measurements that require rapid 
imaging with no delay post dispensing, e.g. fast agonist-induced calcium release. Thirdly, 
the single-cell-based nature of this assay in combination with automated image analysis 
enables the detection of even slight changes in calcium concentration which cannot be 
achieved with the use of conventional single-well-based calcium measurement screening 
technologies (e.g. FLIPR) [309]. Moreover, the ability to simultaneously monitor calcium 
transients for individual cells of a well, allows applying multiple filtering parameters in 
image analysis software to set apart different cell subpopulations from each other, e.g. 
“active” from “inactive”, “responsive” from “non-responsive”, “transfected” from 
“untransfeced” cells, etc. The latter is not possible in single-well-based calcium 
measurement assays. Furthermore, the assay offers superior robustness reflected by Z’-
factor > 0.8. Overall, the aforementioned advantages of the developed HTS assay enabled 
us to identify drugs, which by having even a modest effect on exaggerated IP3R-evoked 
calcium signals may be beneficial for AD therapy. 
 
Calcium alterations associated with FAD-PS expression provide ideal means to 
investigate the disruption of ER calcium homeostasis. FAD-PS-dependent calcium 
alterations in intracellular calcium stores have been linked to synaptic dysfunction, the 
underlying basis of cognitive impairment in AD [310]. Nevertheless, the potential of the 
developed HTS assay is not only restricted to FAD drug discovery. Early studies indicate 
that the disrupted ER calcium release correlates with Aβ and tangle pathologies in AD 
[48]. During physiological aging [52, 311] and in several neurodegenerative diseases [25, 
312] the neuronal store calcium homeostasis is also altered. Yet the alterations in ER 
calcium homeostasis during aging are much more subtle [313]. Notably, age is the main 
risk factor for developing sporadic AD [314]. Moreover, PS1 mutations are also 
associated with heart failure and cardiac diseases as a result of similar alterations in ER 
calcium signaling as in AD [315]. Therefore, targeting intracellular store calcium 
homeostasis in HTS assays may allow the identification of drugs relevant for treatment of 
undesired effects associated with physiological aging and a wide range of 
neurodegenerative and cardiac diseases. As recently reviewed by Chadwick et al., ER is 
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not a classical AD drug target, however due to its multifactorial involvement in several 
cellular aspects of AD, even a modest modulation in its function may present tremendous 
therapeutic efficacy [316].  
 
Screening of over 20,000 small molecules using the HTS assay yielded the discovery of 
four lead structures and 53 primary hit molecules, one of them being Bepridil, a calcium 
channel blocker. Bepridil specifically attenuated the FAD-PS1-mediated exaggerated ER 
calcium release, without affecting the latter in wildtype PS1 expressing cells. Bepridil is 
reported to modulate APP processing by simultaneously affecting the activity of β- and γ-
secretases [299]. Hence, we synthesized 15 Bepridil derivatives in an attempt to identify 
analogous structures with improved efficacy and potency in restoring the exaggerated 
IP3R-evoked calcium release in cells carrying FAD-linked PS1 mutations. However, the 
modifications in the chemical structure of Bepridil did not further improve the activity of 
synthesized derivatives in the ER calcium release assay. 
 
Bepridil treatment increased the activity of AMPK in a dose-dependent manner. We 
demonstrate that Bepridil-associated AMPK activation is indeed a CaMKKβ-dependent 
mechanism, since CaMKKβ inhibitor STO-609 partially abolishes the Bepridil-mediated 
activation of AMPK. Such a partial effect may be due to incomplete CaMKKβ inhibition 
by STO-609 and the residual activity of calcium-stimulated CaMKKβ. 
 
Based on our finding that Bepridil dampens the calcium release from ER, at the first sight 
it may appear that, in contradiction to our hypothesis, Bepridil should lower the AMPK 
activity. However, the control of AMPK activation is a complex mechanism which is 
regulated in a context- and tissue-dependent manner [317]. While calcium can activate 
AMPK, chronic elevated cytosolic calcium concentrations have been shown to lower the 
AMPK activity [318]. The consequence of the FAD-PS-associated exaggerated calcium 
release from ER may also be chronically increased cytosolic calcium concentrations. 
Moreover, both in AD and aging, where long-term disturbed calcium homeostasis is 
present, declined AMPK activity has been described [305, 319]. 
 
Alterations in intracellular calcium homeostasis can directly affect Aβ production [49]. 
Indeed, many of the active compounds identified from the primary calcium screen either 
increased or decreased the production of Aβ peptides. Such a wide range of effects on Aβ 
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generation is rather predictable, since most likely those compounds target different 
components of intracellular calcium homeostasis, thus, also differently affecting APP 
processing. In accordance with the findings of Mitterreiter et al. [299], we also detected 
less Aβ generation upon Bepridil treatment. Here we propose an alternative calcium-
dependent mechanism for the described Bepridil-mediated decrease in β-secretase 
cleavage and the consequent lowered Aβ production [299]. Several publications have 
previously demonstrated that AMPK is implicated in APP metabolism and its 
pharmacological activation is associated with reduced Aβ generation [320, 321]. 
Interestingly the activity of SIRT1, a downstream protein target of AMPK activation, 
leads to lowered Aβ production through ADAM10 activation [322], the major 
physiologically relevant form of APP α-secretase [323]. Moreover, AMPK activation has 
been shown to be associated with reduced expression of BACE1 [324]. Taken together, 
the observed simultaneous Bepridil-dependent increase in sAPPα and decrease in sAPPβ 
cleavage products may respectively be attributed to ADAM10 activation and BACE1 
downregulation, mediated by increased AMPK activity. Indeed, CaMKKβ inhibition with 
STO-609 reversed the Bepridil-dependent increase in secreted sAPPα, however did not 
rescue the decreased sAPPβ levels. This might be due to the fact that BACE1 activity 
itself is calcium-dependent [39], thus interfering with calcium homeostasis and CaMKKβ 
activity may also additionally affect APP processing through calcium-dependent, but 
AMPK-independent mechanisms. 
 
In cells overexpressing C99, which is the β-cleaved product of APP and the substrate for 
γ-secretase, treatment with Bepridil decreased Aβ38 and Aβ40 levels, but on the other 
hand increased Aβ42 amounts. Mitterreiter et al. have also described such a concurrent 
iGSM feature for Bepridil.  This might also explain our observation that in APP-
overexpressing cells, Bepridil treatment at lower concentrations (10 µM and 3 µM) 
increases, but at higher concentration (30 µM) decreases Aβ42 levels. However, Aβ38 
and Aβ40 levels were decreased at all Bepridil concentrations in all cell types tested. In 
other words, it appears that at low Bepridil concentrations, the iGSM effect of Bepridil 
(increase in Aβ42 levels) overbalances the reduced BACE1 activity (decrease in Aβ42 
levels), whereas at higher Bepridil concentrations this effect is visa versa. 
 
There exists evidence that calcium ions can directly regulate the activity of γ-secretase 
[325] and BACE1 [39]. Therefore we cannot exclude the possibility that stabilization of 
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ER calcium by treatment with Bepridil may also reduce the activity of γ-secretase and 
BACE1 and thus lead to lowered Aβ production. Mitterreiter et al. report that APP 
protein expression level is indeed unaffected by Bepridil treatment [299]. Therefore the 
possibility that reduced APP protein levels may account for Bepridil-dependent Aβ 
reduction can be excluded. 
 
Mitterreiter et al. have already described that Bepridil can inhibit β-secretase cleavage by 
mildly raising the membrane-proximal endosomal pH, while independently modulating γ-
secretase activity as well [299]. Here we describe an additional mode of action for 
Bepridil which involves AMPK activation, a mechanism modulating APP processing. 
AMPK activity is implicated in several aspects involved in AD pathogenesis [305]. For 
example, AMPK activation has been shown to promote autophagy and Aβ clearance 
[326, 327] and also regulate tau phosphorylation through direct and indirect mechanisms 
[328, 329]. In view of such promising indications, the potential protective role of Bepridil 
associated with improved Aβ clearance or tau pathology should be examined in more 
complex models.  
 
Novel molecular target(s) of Bepridil are yet to be determined. However, based on the 
known function of Bepridil as a calcium channel blocker, one may speculate that by 
dampening the hyperactivated calcium channels located on the ER [69, 230], Bepridil 
could stabilize the disturbed ER calcium homeostasis. Indeed, treatment with ryanodine 
receptor (RyR) blocker dantrolene was shown to reduce Aβ burden, increase PSD-95 
expression and improve learning and memory in a APPsw-expressing mouse model of 
AD [204]. Moreover, PS holoprotein has been shown to form passive leak calcium 
channel on the ER membrane [228]. Therefore future studies are necessary to closely 
examine whether Bepridil exerts any modulatory effect on the activity of ER calcium 
receptor channels or the passive calcium leakage through PS holoprotein.  
 
In this report, we focused on characterization of Bepridil, a hit identified from the HTS. 
However other lead structures and hits identified from the primary screen may also 
provide therapeutic potential for AD treatment which shall be investigated in future. 
 
 
 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 73 
Acknowledgements 
 
The authors are grateful to Dr. A. Miyawaki for YC3.6 construct, to Dr. A. Kirsch for the 
support in developing image analysis tool, to Dr. T. Hirschberger for his help in data 
mining and SAR studies, to P. Schmitz and F. Wachter for data management, to M. 
Taverna, Drs. S. Lichtenthaler, S. Lammich, H. Steiner and C. Haass for kindly providing 
the stable PS1 and APP lines and the support in the Aβ and sAPPα/β measurements. We 
also would like to thank T. Kares, J. Knörndel and O. Stelmakh for their excellent 
technical assistance. 
74 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
 
 
 
Figure 6.1. CCh–induced calcium release in HEK293 carrying PS1 mutations 
(a) The average peak amplitude of CCh-induced calcium release is significantly potentiated in FAD and 
inactive PS1 mutants compared to wild type PS1 cells (*** P<0.001). 
(b) The average number of responsive cells to CCh is remarkably increased in cells expressing FAD and 
inactive PS1 mutants compared to wild type PS1 cells (*** P<0.001). 
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Figure 6.2. Work flow of the high-throughput FRET calcium imaging based compound screening 
assay and data analysis 
(a) Structure of the calcium sensor YC3.6 which is a fusion protein composed of CFP and YFP attached via 
calmodulin (CaM) and a CaM-binding peptide (M13). Calcium binding brings CFP and YFP together, shifting 
the emission of 480 nm to 535 nm upon excitation at 440 nm. 
(b) CCh application initiates a pathway which results in calcium release from ER. CCh exposure leads to G-
coupled activation of PLC catalyzing the hydrolysis of the membrane-associated PIP2 molecule to IP3. 
Binding of IP3 molecule to IP3 receptor channels (IP3R) on the ER membrane in turn leads to opening of IP3R 
channels and calcium release from ER to cytosol. 
(c) Representative calcium transients of CCh-evoked calcium release in cells expressing FAD-linked PS 
mutant versus wildtype PS. FAD-PS expressing cells show an exaggerated calcium release upon CCh 
exposure. The arrow shows the time point at which CCh is applied. The HTS screening rationale was to 
identify drugs that can restore the FAD-PS-associated potentiation of CCh-evoked calcium release to the 
level of wildtype PS. 
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(d) HEK293 cells stably expressing PS1-M146L and YC3.6 calcium indicator are seeded in 384-well format 
plates. 6-8 h post seeding, using a pipetting robot, library compounds are added to separate wells. After 24 
h, to stain nuclei, DRAQ5 is added to each well using the pipetting robot. After 2 h plates are confocally 
imaged by Opera® system which is equipped with a fast dispensing unit applying CCh to each well during 
time-lapse imaging. An image analysis tool within the Acapella® software is developed to automatically 
analyze single cell calcium transients. Using DRAQ5 nuclear segmentation, image analysis tool detects the 
boundaries of individual cells in the first time point and measures then the intensities of in FRET–acceptor 
and –donor over the course of imaging. The FRET efficiency of individual cells are then calculated and 
normalized. For each cell the signal maximum (peak) is determined. The compounds which attenuated the 
peak amplitude of CCh-induced calcium release to <90% of the DMSO controls were regarded as hit. Finally 
by data mining and determining the structure-activity-relationships (SAR) of the entire library consisting of 
over 20,000 compounds, active lead structures were identified. 
(e) Z’-factor as a measure for the robustness of the screening assay is evaluated for ten randomly selected 
imaged plates. The average Z’-factor for the screened plates exceeded 0.8. 
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Figure 6.3. Active structures identified from primary HTS screen 
Shown are 53 small molecules identified from the primary screen with their chemical structure and the 
corresponding normalized ER calcium response values generated at 10 µM, as a measure for their activity. 
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Figure 6.4. Validation of primary hits, structure-activity-relationship (SAR) analysis and their in vitro 
cytotoxicity 
(a) The activity of all 53 primary hits was validated in PS1-M146L/YC3.6 line. All the hits were capable of 
reducing the peak size of CCh-induced calcium release to <90% of DMSO-treated controls. 
(b) The structure-activity-relationship (SAR) map of the screened compounds. The symbols represent 
compound clusters generated by Benchware DataMiner software. The distance between the clusters 
correlates with the similarity between their chemical structures. The number of compounds within a cluster is 
illustrated by the size of the symbol. A cluster with more than 50% active compounds is represented by a 
star, and marked in blue if the actual number of active compounds is greater than 4. The highlighted 
identified lead structures belong to compound classes Thiazolidine (blue), Phenothiazine (green), Imidazole 
(turquoise) and Benzhydrilpiperidinamin (brown). 
Primary hits were also active in HEK293 cells expressing (e) PS1-DeltaE9/YC3.6, (f) PS1-C92S/YC3.6, and 
(g) PS1-D385N/YC3.6, by attenuating the mutant PS1-induced amplified calcium release.  
(c) and (d) The hits from the primary screen were classified into 8 categories based on their efficacy in 
lowering the CCh-evoked calcium release. These categories are separated according to the value of 
normalized ER calcium response. The noted numbers in each category indicates the number of compounds 
belonging to that catagory. 
(h) Viability of HEK293 cells treated with the primary screen hits was assessed by means of MTT assay after 
24 h compound treatment. Values are presented as percentage of viable cells. 
In (a), (e), (f) and (g), the peak size of DMSO-treated control is set to 1. Each color denotes a different lead 
structure in (a), (b), (e), (f), (g) and (h). The data for analogous molecules belonging to the same lead 
structure are marked with the same color. 
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Figure 6.5. Dose-dependent effect of Bepridil and its derivative structures on the amplitude of CCh-
evoked ER calcium release in PS1-M146L cells 
The effect of Bepridil and its 15 synthesized derivative structures were tested at 30, 10, 3, 1, 0.3 and 0.1 µM. 
The peak size of DMSO-treated control is set to 1. The relative peak amplitude of CCh-evoked calcium 
release is plotted for each treatment condition. Compounds BSc3947 and BSc4209 were toxic at 30 µM 
concentration.  
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Figure 6.6. Effect of on Bepridil on APP processing and AMPK activity 
(a) Reduced production of Aβ38, Aβ40 and Aβ42 after 16 h Bepridil (30 µM) treatment in HEK293 cells 
coexpressing APPsw and PS1-M146L. Sulindac sulfide (50 µM) was used as a γ-secretase modulator 
control.  
(b) Increased levels of sAPPα and decreased sAPPβ secreted fragments after 16 h treatment with Bepridil in 
HEK293 cells coexpressing APPsw and PS1-M146L. 
(c) Dose-dependent activation of AMPK upon 16 h treatment of HEK293 cells with Bepridil. 
(d) Cotreatment with STO-609 (50 µM) partially abolishes the Bepridil-dependent activation of AMPK in 
HEK293 cells. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001). 
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Figure 6.S1. Shown are the 11 compounds belonging to the lead structure Phenothiazine. Their chemical 
structure, physical properties and normalized CCh-evoked calcium release peak size are presented at 10 µM 
as a measure for their activity in the ER calcium release assay. 
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Figure 6.S2. Shown are the 7 compounds belonging to the lead structure Thiazolidine. Their chemical 
structure, physical properties and normalized CCh-evoked calcium release peak size are presented at 10 µM 
as a measure for their activity in the ER calcium release assay. 
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Figure 6.S3. Shown are the 5 compounds belonging to the lead structure Benzhydrilpiperidinamin. Their 
chemical structure, physical properties and normalized CCh-evoked calcium release peak size are presented 
at 10 µM as a measure for their activity in the ER calcium release assay. 
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Figure 6.S4. Shown are the 3 compounds belonging to the lead structure Imidazole. Their chemical 
structure, physical properties and normalized CCh-evoked calcium release peak size are presented at 10 µM 
as a measure for their activity in the ER calcium release assay. 
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Figure 6.S5. Shown are Bepridil and 15 synthesized derivatives, their chemical structure, physical properties 
and the normalized CCh-evoked calcium release peak size at 10 µM as a measure for their activity in the ER 
calcium release assay. 
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Figure 6.S6. The effect of Bepridil on the amplitude of CCh-evoked ER calcium release in wildtype 
PS1-expressing HEK293 cells 
Bepridil (30 µM) does not alter the amplitude of CCh-evoked ER calcium release in wildtype PS1-expressing 
HEK293 cells. The peak size of DMSO-treated control is set to 1. Thapsigargin (1 µM), CPA (20 µM) and 
TMB-8 (50 µM) were used as positive controls. 
(n.s.: non-significant and *** P<0.001). 
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Figure 6.S7. Effect of on Bepridil on APP processing 
(a) Altered production of Aβ38, Aβ40 and Aβ42 after 16 h treatment of APP-overexpressing HEK293 cells 
with Bepridil. DAPT (10 µM), a γ-secretase inhibitor, was used as a positive control. 
(b) Altered production of Aβ38, Aβ40 and Aβ42 after 16 h treatment of C99-overexpressing HEK293 cells 
with Bepridil (30 µM). Sulindac sulfide (50 µM), a γ-secretase modulator, was used as a positive control. 
(c) Increased levels of sAPPα and decreased sAPPβ secreted fragments after 16 h treatment with Bepridil in 
APP-overexpressing HEK293 cells. 
(d) Cotreatment with STO-609 (50 µM) reverses the Bepridil-dependent (30 µM) increase in sAPPα (but not 
the decrease in sAPPβ) in HEK293 cells coexpressing APPsw and PS1-M146L. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001). 
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Figure 6.S8. Effects of the active compounds from the calcium HTS on Aβ production 
Altered production of Aβ38, Aβ40 and Aβ42 after 16 h treatment of HEK293 cells coexpressing APPsw and 
PS1-M146L with the active structures identified from the calcium HTS. DAPT (10 µM) was used as a γ-
secretase inhibitor control.  
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7.1 Abstract 
 
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder and the most 
frequent cause of dementia. To date, there are few approved drugs for AD, which show 
little or no effect on disease progression. Impaired intracellular calcium homeostasis is 
believed to occur early in the cascade of events leading to AD. Here we examined the 
possibility of normalizing the disrupted calcium homeostasis in the endoplasmic 
reticulum (ER) store as an innovative approach for AD drug discovery. High-throughput 
screening of a small-molecule compound library led to the identification of 
tetrahydrocarbazoles, a novel multifactorial class of compounds that can normalize the 
impaired ER calcium homeostasis. We found that the tetrahydrocarbazole lead structure, 
firstly, dampens the enhanced calcium release from ER in HEK293 cells expressing 
familial Alzheimer's disease (FAD)-linked presenilin 1 mutations. Secondly, the lead 
structure also improves mitochondrial function, measured by increased mitochondrial 
membrane potential. Thirdly, the same lead structure also attenuates the production of 
amyloid-beta (Aβ) peptides by decreasing the cleavage of Amyloid Precursor Protein 
(APP) by β-secretase, without notably affecting α- and γ-secretase cleavage activities. 
Considering the multiple modes of action of tetrahydrocarbazoles in addressing three key 
pathological aspects of AD, these compounds hold promise for development of a 
potentially effective AD drug candidate. 
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7.2 Introduction 
 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly [293]. 
Currently, there is no effective therapeutic modality for prevention, halting or reversal of 
AD [330]. The two principal neuropathological hallmarks of AD are the accumulation of 
extracellular plaques of β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles 
of hyperphosphorylated tau protein in the brain. Aβ and tau are thus the prime drug 
targets for development of disease-modifying therapy in AD [293]. Nevertheless, the lack 
of breakthrough in effective therapy, along with the consistent failure of drug candidates 
targeting late-stage Aβ and tau pathologies in clinical trials, have recently led to a major 
shift in the search for alternative AD drug targets [14]. Importantly, dysregulated calcium 
signaling plays a central role in AD pathogenesis [22, 29], for example by triggering both 
Aβ and tau pathology [48, 50]. Indeed, calcium imaging with cells derived from mild-
cognitive-impairment (MCI) subjects, familial and sporadic AD patients [46, 229], and 
neurons from transgenic AD mouse models [331] indicate that disturbances in 
endoplasmic reticulum (ER) calcium homeostasis are early events in AD pathogenesis, 
most likely preceding the clinical manifestation of the disease [41]. Practically, every 
gene that is known to directly cause AD or increase susceptibility to it, somehow also 
affects calcium homeostasis [22]. Hence, therapeutic interventions aiming at preventing 
such early calcium dyshomeostasis have been proposed to present a promising 
opportunity for disease-modifying therapy of AD [6]. Furthermore, due to the 
multifactorial involvement of ER in the pathogenesis of AD, even minimal levels of 
therapeutic modulation in the ER may yield tremendous therapeutic efficacy [316]. In 
light of such indications and the novelty of this approach, we developed and performed a 
high-throughput screen for small-molecule compounds that can normalize the enhanced 
agonist-evoked ER calcium release phenotype in HEK293 cells expressing FAD-linked 
Presenilin-1 (PS1) mutations. Various mechanisms have been proposed to underlie the 
FAD-PS1-mediated enhancement of the ER calcium release, e.g. enhanced inositol 1,4,5-
trisphosphate (IP3) and ryanodine receptor (RyR) channel activities, altered 
sarcoendoplasmic reticulum calcium transport ATPase (SERCA) pump function, 
decreased capacitative calcium entry and loss of ER passive calcium leakage [255]. 
Irrespective of the controversies in the field as to which of these are the primary causative 
and which the secondary phenomena, we performed a large-scale phenotypic compound 
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screening [332]. This resulted in identification of a novel class of chemical structures that 
normalize the exaggerated calcium release from ER in cells expressing a FAD-PS1 
mutation. Stabilization of calcium signaling by the identified lead structure was 
accompanied by improved mitochondrial function and decreased Aβ peptide production. 
 
7.3 Material and Methods 
 
7.3.1 Cell culture and cell lines 
 
Human embryonic kidney 293 (HEK293) cells were cultured in Dulbecco’s modified 
eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin while being incubated at 37°C, 5% CO2 and 90% humidity. The 
stable PS1 lines (generously provided by Dr. S. Lammich) were carrying PS1 variants 
that were cloned into pcDNA3.1/Zeo(+) and single cells were selected via Zeocin 
antibiotic resistance [333, 334]. The PS1 lines were then stably transfected with 
YC3.6/pcDNA3 construct (kindly provided by Dr. A. Miyawaki) and single cells were 
respectively isolated by G418 antibiotic resistance leading to generation of double stable 
lines. The APP- , C99- and APPsw/PS1-M146L-overexpressing HEK293 lines were 
kindly provided by Dr. S. Lichtenthaler and Dr. H. Steiner and cultured as previously 
described [299, 300]. 
 
7.3.2 Automated high-throughput FRET-based calcium imaging and image analysis 
 
HEK293 cells stably expressing PS1-M146L and Yellow Cameleon 3.6. (YC3.6) [212], 
were seeded at 13,000 cells/well in 40 µl of growth medium on collagen-coated 384-well 
CellCarrier plates (PerkinElmer, Rodgau, Germany). After 6 h, using an automated 
pipetting robot (Bravo, Agilent Technologies, Santa Clara, CA, USA), library compounds 
were added to each well at the final concentration of 10 µM in 1% DMSO, each in 4 
replicates. All plates contained Thapsigargin (TP; 1 µM; Calbiochem, Darmstadt, 
Germany), Cyclopiazonic acid (CPA; 20 µM; Calbiochem), 3,4,5-trimethoxybenzoic acid 
8-(diethylamino)octyl ester (TMB-8; 50 µM; Sigma-Aldrich, Taufkirchen, Germany) and 
Bepridil (20 µM; Sigma-Aldrich) as positive controls reducing the amount of calcium 
release from ER, as well as untreated and DMSO vehicle-treated wells. After 24 h using 
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the pipetting robot, DRAQ5 (Biostatus Ltd, Leicestershire, UK), a far-red fluorescent 
nuclear dye, was added to each well at the final concentration of 500 nM. After 2 h, plates 
were measured for CCh-induced calcium release using Opera® high-throughput confocal 
imaging platform (PerkinElmer Cellular Technologies GmbH, Hamburg, Germany). 
Throughout imaging of the entire plate, 37°C temperature, 5% CO2 and 90% humidity 
was maintained in the plate chamber. Using a 442 nm laser, YC3.6 was excited and its 
CFP and YFP emissions were separated respectively using 483/35 nm and 540/75 nm 
filters. Additionally, using a 640 nm laser DRAQ5 dye was excited and its emission was 
collected by 690/50 nm filter in order to locate the nuclei. Imaging was performed with a 
20x water immersion autofocus objective. The duration of the entire time-lapse calcium 
imaging for each well was 23.5 s. This was achieved by imaging at 2.5 s interval 
resolution prior to dispensing CCh (for 5 s) to monitor the basal calcium levels. Next, the 
CCh-induced calcium rise and decay were monitored for 18.5 s post dispensing. Imaging 
was performed first at 1 s interval resolution immediately after dispensing (for 5 s) and 
subsequently at 2.5 s interval resolution (for 12.5 s). During dispensing, 10 µl of CCh 
(Calbiochem) diluted in HBSS (10 µM) was injected to each well concurrent with 
calcium imaging by an automated dispensing unit which is part of the Opera® platform. 
Imaging was performed sequentially for all 384 wells. Using Acapella® software 
(PerkinElmer Cellular Technologies GmbH), an automated image analysis tool was 
developed to translate fluorescent signals to numerical values. Here, DRAQ5 and YC3.6 
signals were used respectively to detect single cell nuclei and single cell boundaries over 
the entire course of time-lapse calcium imaging. After assigning each cell to its 
segmented nuclei and excluding the cells positioned at the edges of the imaging frames, 
calcium transients for every cell were monitored by plotting the kinetics of YFP/CFP 
versus time and normalizing the signals using the equation, ΔF/F0 = (F – F0)/ F0, where F 
is the measured fluorescence signal at any given time and F0 is the average fluorescence 
signal of the time points preceding CCh application. The peak amplitude of calcium rise 
upon CCh injection was the output of automated image analysis at single cell level. Non-
responsive cells to CCh were excluded from analysis by setting an arbitrarily defined 
threshold. The average peak amplitude of all responsive cells in each well was calculated 
as the final readout in this assay. 
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7.3.3 Mitochondrial membrane potential TMRM assay 
 
The measurement method for mitochondrial membrane potential with TMRM dye was 
adapted from Scaduto et al. [335]. HEK293 cells were seeded at the density of 50,000 
cells/well on collagen/poly-L-lysine (PLL)-coated 96-well plates (Advanced-TC plates, 
Greiner Bio-One GmbH, Frickenhausen, Germany) and incubated for 24 h. Next, the cells 
were loaded with 50 nM tetramethylrhodamine methyl ester (TMRM; Invitrogen, 
Carlsbad, CA, USA) dye in the presence of either tetrahydrocarbazoles analogues (10 
µM), positive control Dimebon (10 µM; Sigma-Aldrich), or DMSO vehicle which were 
pre-incubated on the cells 1 h prior to adding of TMRM dye. After 30 min each well was 
washed 3 times using PBS. Fresh medium containing each of the corresponding tested 
compounds (10 µM) was added into the wells. Live cell image acquisition was performed 
using inverted confocal microscope LSM510 with 25x magnification (Carl Zeiss 
MicroImaging GmbH, Jena, Germany) and the images were analyzed using ImageJ (NIH, 
USA) software to quantify the intensity of TMRM fluorescence signal. All measurements 
were performed with at least eight replicates. 
 
7.3.4 Aβ measurements 
 
The levels of three different Aβ species (Aβ38, Aβ40 and Aβ42) were measured using 
sandwich ELISA. Pools of HEK293 cells stably transfected with either APPsw/PS1-
M146L or APP were used to study the effect of compounds on Aβ generation. According 
to Page et. al. [300], cells were seeded at a density of 200,000 cells/well in collagen/poly-
L-lysine (PLL)-coated 24-well plates and incubated for 24 h in growth medium. Next, the 
medium was exchanged with 500 µl of fresh medium containing either the tested 
compounds, or the positive controls DAPT (10 µM, Calbiochem), Sulindac sulfide (50 
µM, Sigma-Aldrich), Bepridil (30 µM, Sigma-Aldrich) [299], or DMSO vehicle. After 16 
h conditioned medium was collected and the levels of secreted Aβ38, Aβ40 and Aβ42 
fragments were quantified using “Human (6E10) Abeta 3-Plex” sandwich ELISA 
immunoassay kit (Meso Scale Discovery, Rockville, MD, USA) according to the 
instructions of the manufacturer. In brief, 150 µl of blocker reagent was added to each 
well and incubated for 1 h at room temperature, followed by 3x washing using TRIS wash 
buffer. Next, 25 µl of detection antibody was added to each well. At appropriate dilution, 
each of the samples or calibration standards were added to separate wells of ELISA plate 
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and incubated for 2 h at room temperature, followed by 3x washing using TRIS wash 
buffer. Finally, 150 µl of read buffer was added to the wells. The light emission after 
electrochemical stimulation was measured using Sector Imager 2400 reader (Meso Scale 
Discovery). Based on the values generated with calibration standards, corresponding 
concentrations of Aβ species were calculated using the Meso Scale Discovery Workbench 
software. All measurements were performed with at least two replicates. 
 
 
7.3.5 sAPPα and sAPPβ measurements 
 
Levels of sAPPα and sAPPβ fragments were measured using sandwich ELISA adapted 
from Colombo et al. [336]. Wild type HEK293 cells were seeded at a density of 200,000 
cells/well in collagen/poly-L-lysine (PLL)-coated 24-well plates and incubated for 24 h in 
growth medium. Next, the medium was exchanged with 500 µl of fresh medium 
containing either compounds or vehicle. After 16 h conditioned medium was collected 
and the levels of secreted sAPPα and sAPPβ fragments were quantified using 
sAPPα/sAPPβ sandwich ELISA immunoassay kit (Meso Scale Discovery) according to 
the instructions of the manufacturer. Briefly, 150 µl of blocker reagent was added to each 
well of the ELISA plate and incubated for 1 h at room temperature, followed by 3x 
washing using TRIS wash buffer. Next, 25 µl of samples or calibration standards were 
added to separate wells of ELISA plate and incubated for 1 h at room temperature, 
followed by 3x washing using TRIS wash buffer. Then 25 µl of detection antibody was 
added to each well and incubated for 1 h at room temperature, followed by 3x washing 
using TRIS wash buffer. Finally, 150 µl of read buffer was added to the wells. The light 
emission after electrochemical stimulation was measured using Sector Imager 2400 
reader (Meso Scale Discovery). Based on the values generated with calibration standards, 
corresponding concentrations of sAPPα and sAPPβ were calculated using the Meso Scale 
Discovery Workbench software. All measurements were performed in four replicates. 
 
7.3.6 Statistical data analysis 
 
GraphPad Prism 5.0b (GraphPad Software, San Diego, CA, USA) was used for statistical 
analysis of the data. For comparison and p-value determination, we used one-way 
analysis of variance (ANOVA) method, followed by Dunnett's multiple comparison test. 
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All data are represented as means ± standard deviation. Differences were considered 
statistically significant if p < 0.05. 
 
7.4 Results  
 
7.4.1 Discovery of a novel lead structure from a high-throughput compound screen 
targeting disrupted ER calcium homeostasis 
 
In light of growing evidence towards the role of impaired intracellular store calcium 
homeostasis in the pathogenesis of Alzheimer’s disease [271], here we screened for low-
molecular-weight compounds that can normalize the disrupted ER calcium homeostasis. 
We chose the potentiated agonist-evoked ER calcium release in FAD-PS1-expressing 
cells as a robust phenotypic model to target ER calcium dyshomeostasis for AD drug 
discovery [332, 337]. 
 
All mutant PS1 lines tested revealed remarkably enhanced calcium release when 
compared to wild type PS1-expressing cells (Figure 7.1a). A phenotypic screening for 
compounds that are capable of dampening the potentiated Carbachol (CCh)-evoked ER 
calcium release in PS1-M146L HEK293 cells was subsequently performed. Screening a 
diverse compound library consisting of 20,000 small molecules led to the discovery of a 
novel lead structure. Six recognized analogues of the lead structure in the library, which 
showed activity in the screen (Figure 7.1b), remained active across several other mutant 
PS1-expressing lines (Figure 7.1c, d, e). Importantly, the amplitude of CCh-evoked 
calcium release in wild type PS1 expressing cells was not significantly altered (Figure 
7.1f). For the primary screen, a compound was regarded as active if it reduced the peak 
amplitude of CCh-induced calcium release to <90% of DMSO-treated controls 
(normalized ER calcium < 0.9). 
 
The discovered lead structure, identified as and hereafter called tetrahydrocarbazoles, 
consists of a core moiety having two variable R groups, shown as R1 and R2 (Figure 
7.1g). Comprehensive data mining revealed that the entire compound library contained 10 
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analogues of the lead structure, 8 of which were found to be active in the screen (Figure 
7.1g). 
 
7.4.2 Tetrahydrocarbazoles attenuate the FAD-PS1 mediated exaggerated ER 
calcium release 
 
In order to explore the contribution of different R1 and R2 groups to the activity of the 
lead structure, we further tested 28 commercially available tetrahydrocarbazole analogues 
and related structures. We also validated the activity of the 10 structures previously 
identified from the primary screen (Figure 7.2a and 7.S1). Based on the structure-activity-
relationship (SAR) knowledge gained, we synthesized 23 further derivative structures 
with the aim of reaching an improved efficacy (Figure 7.2b and 7.S2). Replacement of 
nitro group at R1 position with other electron-withdrawing substituents, e.g. halogens, 
trifluoromethyl, and cyano groups, maintains the activity of the lead structure, while other 
small substituents, e.g. hydrogen, lead to the loss of activity. Aliphatic residues at R2 
position (e.g. 5781439, 5781448, 5781457, gea_87) diminish that effect, while additional 
attachment of an aromatic motif (e.g. phenyl group) is beneficial to the activity (e.g. 
5781464, 5781441). 
 
7.4.3 Tetrahydrocarbazoles increase the mitochondrial membrane potential 
 
It has been demonstrated that ER and mitochondria are physically and functionally 
interdependent [338]. Constitutive calcium release from IP3R to mitochondria is a crucial 
mechanism involved in mitochondrial function [126]. Indications suggest that FAD-PS 
mutations affect the physical interaction between ER and mitochondria [339], leading to 
altered shuttling of calcium between the two organelles and modulating the mitochondrial 
calcium uptake [127]. Thus, in the next set of experiments we explored whether the 
modulation of ER calcium homeostasis by the lead structure also affects mitochondrial 
function. To that end, we analyzed mitochondrial membrane potential as an important 
parameter for addressing mitochondrial activity. We used TMRM dye, a fluorescent 
rhodamine derivative, to monitor mitochondrial membrane potential [335]. Indeed, 
pretreatment of HEK293 cells for 1 h with several lead structure analogues led to a 
remarkable increase in the mitochondrial membrane potential, measured by the TMRM 
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fluorescence signal (Figure 7.3a and 7.3b). At 10 µM, the increases in mitochondrial 
membrane potential after treatment with many of the analogues were comparable or even 
superior to that for Dimebon, a known enhancer of mitochondrial activity [152] (Figure 
7.3a and 7.3b). We particularly found that compounds 5781464 and 5781441, 
respectively possessing N-(1-benzylpiperidin-4-yl) and N-(1-phenethylpiperidin-4-yl) 
groups at their R2 position, were among the most active compounds both in terms of 
efficacy and potency (Figure 7.3b and 7.3d). Therefore, in several lead structure 
derivatives that we synthesized, the R2 position remained incorporating N-(1-
benzylpiperidin-4-yl) or N-(1-phenethylpiperidin-4-yl) groups, while we varied the 
groups at R1 position to explore their influence on the activity of the lead structure 
(Figure 7.S2). Indeed the latter analogues were also among the most active synthesized 
compounds in enhancing mitochondrial function (Figure 7.3c). Therefore, we concluded 
that the highest activity in terms of improving mitochondrial membrane potential is 
achieved if the lead structure possesses N-(1-benzylpiperidin-4-yl) or N-(1-
phenethylpiperidin-4-yl) groups at R2 position, given that R1 position incorporates 
electron-withdrawing residues. Exemplarily, the EC50 for one of the most promising 
synthesized derivatives of the lead structure (gea_133; R1 : cyano) was determined to be 
at the therapeutically relevant value of 4.84 µM (Figure 7.3d). Moreover, the efficacy of 
compound gea_133 was remarkably higher than the one of Dimebon, especially at 
concentrations beyond 1 µM (Figure 7.3d). 
 
7.4.4 Tetrahydrocarbazoles lower Aβ peptide production 
 
Next, we studied the impact of tetrahydrocarbazoles on the production of Aβ peptides. 
Modulation of intracellular calcium homeostasis directly affects Aβ production [49]. 
Thus, we hypothesized that normalizing the disrupted ER calcium homeostasis may 
additionally result in lowered Aβ production. Indeed we detected remarkably decreased 
levels of secreted Aβ38, Aβ40 and Aβ42 peptides upon 16 h treatment of HEK293 cells 
expressing either APPsw/PS1-M146L or wildtype APP with the lead structure analogues 
at 10 µM (Figure 7.4a, 7.4c and 7.S3). The IC50 of the select analogues in terms of 
decreasing levels of all three Aβ species lies in the low micromolar range (Figure 7.5a, b, 
c). However, compound treatment in both cell lines did not affect the Aβ42/Aβ40 ratio 
for most analogues, suggesting that the identified lead structure is not a γ-secretase 
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modulator (Figures 7.4b, 7.4d and 7.S4). In order to investigate the γ-cleavage of APP 
independently from its β-cleavage, we used HEK293 cells expressing C99, the β-cleaved 
C-terminal fragment of APP and the substrate for γ-secretase. Here we observed that 
treatment of HEK293-C99 cells with the majority of the lead structure derivatives tested, 
did not (or only marginally) affect the production of Aβ38, Aβ40 and Aβ42 (Figure 7.6a). 
Moreover, Aβ42/Aβ40 ratios remained unaffected upon exposure of HEK293-C99 cells 
with the lead structure analogues (Figure 7.6b). Taken together, these results support the 
conclusion that the detected decrease in Aβ peptide levels is not a γ-secretase-dependent 
phenomenon. In accordance, we postulated that reduced β-cleavage of APP may 
contribute to lowered Aβ generation. Hence, we measured the levels of sAPPα and 
sAPPβ, the first cleavage products of APP, generated by α-secretase and β-secretase, 
respectively. Indeed, we detected significantly decreased levels of secreted sAPPβ, while 
sAPPα levels were unaffected (or only mildly reduced) upon treatment of wildtype 
HEK293 cells with most lead structure derivatives (Figure 7.4e). These results imply that 
the attenuated Aβ production caused by the lead structure is mediated through decreased 
cleavage of APP by β-secretase. The SAR analysis among the lead structure analogues in 
terms of lowering Aβ production was comparable to their determined SAR for increasing 
mitochondrial membrane potential. We found that analogues incorporating electron-
withdrawing residues at R1 position, in combination with N-(1-benzypiperidin-4-yl) or N-
(1-phenethylpiperidin-4-yl) at R2 show the most robust reduction in Aβ production 
(Figure 7.4a). 
 
7.5 Discussion  
 
Dysfunction and loss of neurons and synapses are by far the best available correlates of 
cognitive deficits in AD patients [53, 297]. Regulation of calcium homeostasis is essential 
for neuronal function and synaptic activity [27]. Early-stage aberrant calcium signaling in 
AD is proposed to underlie the late-stage synaptic dysfunction and memory deficits [98]. 
Notably, alterations in ER calcium channels were found to correlate with neurofibrillary 
and Aβ pathologies of AD brain [48]. Moreover, altered calcium homeostasis in 
peripheral tissues was proposed as diagnostic biomarkers of mild AD [46, 47]. 
Furthermore, the beneficial effects of Memantine, an NMDA receptor antagonist, for 
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treatment of moderate-to-severe AD patients reinforce the relevance of calcium-
signaling-targeted AD therapy [37]. Indeed, pharmacological normalization of disrupted 
ER calcium signaling by blocking hyperactivated RyR channels with dantrolene was 
demonstrated to restore synaptic transmission and plasticity, decrease Aβ burden, 
increase PSD-95 expression, and improve learning and memory in different AD mouse 
models [203, 204]. Altogether, given the central role of calcium both in triggering the 
early disease-initiating pathomechanisms as well as accelerating the AD pathology at 
later stages [294], targeting altered calcium signaling presents an attractive target for both 
AD prevention and treatment. Accordingly, we developed and performed a high-
throughput screen for compounds that can normalize the aberrant ER calcium 
homeostasis phenotype caused by FAD-linked PS1 mutations [255]. This approach led to 
the discovery of tetrahydrocarbazoles, a novel lead structure capable of lowering the 
exaggerated CCh-evoked ER calcium release in FAD-PS1 cells. 
 
In addition to the stabilization of ER calcium homeostasis, we observed that 
tetrahydrocarbazoles can improve mitochondrial function, measured by increased 
mitochondrial membrane potential. Mitochondrial dysfunction is proposed to act as a 
trigger in AD pathogenesis and a contributing factor to both onset and progression of the 
disease [134]. In addition to aberrant calcium homeostasis, mitochondrial dysfunction is 
an additional early event in the course of AD, thus presenting an attractive target for 
preventative therapy [340]. Growing body of evidence indicates that the ER–
mitochondria physical interfaces and calcium shuttling between the two organelles 
through IP3 receptors play a crucial role in the regulation of mitochondrial function [126], 
which appears to be affected in AD [127, 339]. Treatment with many of the lead structure 
derivatives resulted in a larger increase in the mitochondrial membrane potential than 
treatment with Dimebon. The latter suggests higher efficacy for tetrahydrocarbazoles 
compared to Dimebon. Despite not having reached the efficacy endpoints in clinical 
phase III, Dimebon is a drug which is thought to be beneficial in particular stages of the 
disease [341]. It was demonstrated that Dimebon can improve cognitive functions in 
mild-to-moderate Alzheimer’s disease patients [342, 343], presumably by enhancing the 
mitochondrial activity [152, 344]. 
 
We also found that treatment with many tetrahydrocarbazole analogues results in notably 
less Aβ38, Aβ40 and Aβ42 production in two different cell lines. Yet, Aβ42/Aβ40 ratios 
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remained largely unchanged. The latter indicates that the identified lead structure does not 
possess the properties of a γ-secretase modulator (GSM). GSMs are characterized by 
decreased production of longer Aβ species (e.g. Aβ42) accompanied by increased 
generation of shorter Aβ species (e.g. Aβ38 and Aβ40), resulting in lowering of 
Aβ42/Aβ40 ratio [161]. Although there is evidence that γ-secretase activity may be 
affected by calcium ions [325], the detected decreases in Aβ levels were not 
predominantly caused by γ-secretase inhibition. The evidence for the latter comes from 
the experiments with HEK293-C99 cells, suitable for exclusively addressing the γ-
secretase cleavage of APP (independently from β-secretase activity). In HEK293-C99 
cells, we detected unchanged or only slightly decreased Aβ levels upon treatment with the 
derivative structures tested. These minor reductions in Aβ levels caused by some lead 
structure derivatives can be due to the fact that calcium ions can modulate the γ-secretase 
activity to some extent [325]. However, such minor effects cannot account for the 
remarkable decrease in Aβ levels observed after treatment of APPsw/PS1-M146L and 
APP-expressing cells with tetrahydrocarbazole analogues. Our findings rather suggest 
that lowered Aβ production is mainly attributed to decreased β-cleavage of APP. We 
detected remarkably decreased sAPPβ levels upon exposure of HEK293 cells with the 
lead structure derivatives. Indeed, it has been demonstrated that calcium directly enhances 
the proteolytic activity of β-secretase (BACE1) [39]. Therefore, it is plausible that 
stabilization of ER calcium homeostasis by the lead structure results in lowered BACE1 
activity and consequently decreased Aβ production. The decrease in sAPPβ was not 
accompanied by an increase sAPPα, indicating that the lead structure does not alter the α-
secretase cleavage activity. The lack of inverse coupling between α- and β-secretase 
activities in frequently used cell lines, e.g. HEK293 cells, may explain our finding that the 
lead structure lowers sAPPβ generation without changing sAPPα levels [336]. The 
observation that most lead structure analogues do not affect Aβ and sAPPα levels, 
respectively in HEK293-C99 and wildtype HEK293 cells (e.g. gea_133), indicates that 
the decreased Aβ production through lowering β-cleavage of APP is indeed a specific 
effect which is not caused by reduced protein production. 
 
The structure-activity-relationship analysis revealed that the effect of lead structure 
analogues is most prominent with specific residues at C-6 (R1) and the exocyclic amino 
group (R2). We found that when R1 represents halogens and other electron-withdrawing 
substituents, e.g. nitro, trifluoromethyl, and cyano, this leads to a strong increase in 
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mitochondrial membrane potential, while also strongly attenuating Aβ peptide production 
and ER calcium release.  On the other hand, substitution at C-7 and C-8 (gea_84) was 
found to be detrimental to the activity. Furthermore, N-methylation at either the pyrrole 
nitrogen (gea_90) or the side chain secondary amino group (gea_92) led to the complete 
loss of the activity. Merely aliphatic residues at the exocyclic nitrogen (R2; i.e. 5781439, 
5781448, 5781457, gea_87) result in lowering or loss of the activity, while additional 
attachment of an aromatic motif (phenyl group) shows benefit in all three assays (i.e. 
5781464, 5781441). The best effect in all of the three assays was detectable for 
tetrahydrocarbazoles containing a diamino side chain R2 (aminopiperidine) with an 
attached N-benzyl or N-phenethyl residue (i.e. 5781441, 5781464, gea_96, gea_97, 
gea_101, gea_102, gea_130, gea_133). Therefore, by a systematic optimization of lead 
structure analogues, we generated a subclass of compounds that are highly active in all 
three assays. 
 
The vast majority of AD patients are sporadic late-onset cases and age remains the main 
risk factor for developing sporadic AD [345]. Importantly, aging process involves 
disturbances in the intracellular calcium homeostasis, particularly in ER and mitochondria 
[346, 347]. Lymphocytes derived from sporadic AD patients show elevated cytosolic 
basal calcium concentrations and disturbed ER calcium homeostasis [46, 348]. Every 
gene that is known to increase susceptibility to AD also modulates some aspect of 
calcium signaling [22]. In particular, a polymorphism in the CALHM1 gene encoding an 
ion channel’s pore-forming subunit that affects intracellular calcium homeostasis has 
been linked to susceptibility to sporadic AD [71, 349]. Along with the ER stress, 
mitochondrial damage also contributes to aging process [350].  Moreover, sporadic AD is 
associated with reduced mitochondrial membrane potential [351] as well as elevated 
BACE1 activity [352] which in turn leads to increased Aβ production and plaque 
deposition [353]. Therefore we predict that the benefits of tetrahydrocarbazoles, will not 
be limited to familial AD cases, but also may present a high potential for sporadic AD 
cases as well (patent pending; PCT/EP2013/055969). 
 
It is established that modulation of ER calcium homeostasis can affect mitochondrial 
function [126] and APP metabolism [49]. However, since the direct molecular target(s) of 
tetrahydrocarbazoles remain unknown, this study is limited by the fact that we cannot 
firmly conclude that the improved mitochondrial activity and decreased Aβ production 
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are downstream effects of normalizing calcium homeostasis. Therefore, future studies 
addressing the exact molecular target(s) of tetrahydrocarbazole lead structure and their 
detailed therapeutic mode of action are of utmost importance. Whether or not the 
beneficial effects of tetrahydrocarbazoles on calcium homeostasis, mitochondrial function 
and APP processing follow a dependency, should not, however jeopardize the therapeutic 
relevance of this discovery. Another important open question which remains to be 
elucidated is whether tetrahydrocarbazoles also reverse the late-stage Aβ-plaque-
dependent calcium disturbances in the brain [89, 90], which may be caused by Aβ-
induced calcium release from ER [354]. Apart from IP3 receptor channel gating itself 
[69], multiple upstream elements of IP3R-mediated calcium release are affected in AD, 
e.g. GPCR in general [355], and muscarinic receptors in particular [356], G-proteins 
[357], as well as PLC [358]. Given that the screening hits may potentially target any of 
those upstream elements, such a phenotypic multi-targeted drug screening assay provides 
the important advantage of collectively addressing several aspects of AD. 
 
AD is believed to be a multifactorial disease, caused by complex interactions among 
several contributing pathomechanisms [330, 359]. Nevertheless, the majority of current 
disease-modifying drug development strategies address only single aspects of the disease. 
Therefore, similar to combinational therapy [330], drugs such as tetrahydrocarbazoles 
which simultaneously address several central pathophysiological aspects of AD are 
clearly of advantage. 
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Figure 7.1. Tetrahydrocarbazole analogue screening hits/lead structure and their effects on FAD-PS1-
mediated disrupted ER calcium release 
(a) The peak amplitude of CCh-evoked calcium release in HEK293 cells expressing wild type PS1, FAD-
linked (PS1-M146L, PS1-C92S and PS1-DeltaE9) or a γ-secretase deficient (PS1-D385N) PS1 mutations. 
The effect of six tetrahydrocarbazole hits identified from the primary screen at 10 µM in (b) PS1-M146L, (c) 
PS1-C92S, (d) PS1-DeltaE9, (e) PS1-D385 and (f) wild type PS1 expressing HEK293 cells on the peak 
amplitude of CCh-evoked calcium release. CPA, an inhibitor of calcium-dependent ATPases, was used as a 
positive control. (g) The tetrahydrocarbazole lead structure, identified from a high-throughput compound 
screen for substances stabilizing the exaggerated CCh-evoked calcium release in PS1-M146L HEK293 
cells. Illustrated are chemical structures of the ten tetrahydrocarbazole analogues present in the entire 
screened compound library. The upper and lower panels indicate, respectively, eight active and two inactive 
analogues of the lead structure. Compounds capable of reducing the peak amplitude of CCh-induced 
calcium release to <90% of DMSO-treated controls (normalized ER calcium < 0.9) were regarded as active 
hits. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=4). 
 
DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS | 107 
 
 
Figure 7.2. The effects of tetrahydrocarbazole analogues on the FAD-PS1-mediated disrupted ER 
calcium release 
(a) The activity of commercially available and (b) synthesized tetrahydrocarbazole analogues tested at 10 
µM in PS1-M146L HEK293 cells. The presented values indicate the normalized peak amplitude of CCh-
evoked calcium release for cells treated with each compound for 24 h relative to the peak amplitude of 
DMSO-treated control (normalized ER calcium). Compounds marked with # symbol possess a certain level 
of toxicity which interferes with calcium release measurement in this assay. TP (1 µM), CPA (20 µM), TMB-8 
(50 µM) and Bepridil (20 µM), all lowering the amount of calcium release from ER, were used as positive 
controls. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=4). 
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Figure 7.3. The effect of tetrahydrocarbazole analogues on mitochondrial membrane potential 
(a) Representative TMRM staining images of HEK293 cells pretreated for 1 h with the indicated 
tetrahydrocarbazole analogues (10 µM) or Dimebon (10 µM) as a positive control, relative to DMSO-treated 
control (scale bars: 100 µm). 
(b) Quantification of the average TMRM staining signals showing relative intensity for commercially available 
analogues of the tetrahydrocarbazole lead structure upon 1 h pretreatment of HEK293 cells (10 µM). The 
bars highlighted with single- and double-stripes represent the most active compounds 5781464 and 
5781441, which respectively possess N-(1-benzylpiperidin-4-yl) and N-(1-phenethylpiperidin-4-yl) groups at 
their R2 position. 
(c) Quantification of average TMRM intensity for synthesized tetrahydrocarbazole derivatives tested at 10 
µM. The marked single-striped bars represent the analogous structures similar to 5781464, possessing N-(1-
benzylpiperidin-4-yl) at their R2 position, and double-striped bars represent derivative compounds similar to 
5781441, which contain N-(1-phenethylpiperidin-4-yl) group at R2 position. 
(d) Quantification of average dose-dependent TMRM relative intensities for 3 select analogues of the lead 
structure tested at 6 different concentrations relative to Dimebon. The EC50 of all analogues tested lies at low 
micromolar range. 
All values are normalized to DMSO value, which is set to 1. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=8). 
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Figure 7.4. The effect of tetrahydrocarbazoles on APP processing 
(a) Relative Aβ38, Aβ40 and Aβ42 levels, decreased after 16 h treatment with synthesized 
tetrahydrocarbazole derivatives at 10 µM in HEK293 cells coexpressing APPsw and PS1-M146L. Sulindac 
sulfide (50 µM) a γ-secretase modulator, and DAPT (10 µM) a γ-secretase inhibitor, were used as positive 
controls. Inside of the box, a schematic illustration of APP processing by α-, β- and γ-secretase is presented. 
(b) Relative Aβ42/Aβ40 ratios calculated from (a). Treatment with the majority of the lead structure 
derivatives does not alter Aβ42/Aβ40 ratio, whereas positive control Sulindac sulfide significantly lowers 
Aβ42/Aβ40 ratio. 
(c) Relative Aβ38, Aβ40 and Aβ42 levels are decreased after 16 h treatment with select tetrahydrocarbazole 
derivatives at 10 µM in HEK293 cells overexpressing wild type APP. 
(d) Relative Aβ42/Aβ40 ratios calculated from (c). Treatment with select lead structure derivatives tested 
does not alter Aβ42/Aβ40 ratio. 
(e) Relative sAPPα and sAPPβ levels after 16 h compound treatment in wild type HEK293 cells. Treatment 
with select tetrahydrocarbazole derivatives does not (or only marginally) affect secreted sAPPα levels, 
whereas secreted sAPPβ fragment levels are remarkably decreased. 
All values are normalized to the value of DMSO, which is set to 1. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=2). 
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Figure 7.5. Dose-dependent effects of tetrahydrocarbazole derivatives on Aβ production 
The effect of three select synthesized derivatives of tetrahydrocarbazole lead structure on the production of 
(a) Aβ38, (b) Aβ40 and (c) Aβ42 peptides tested at 6 different concentrations in APPsw/PS1-M146L-
expressing HEK293 cells. The IC50 of all Aβ species for all derivative structures tested lies at low micomolar 
range. All values are normalized to the value of DMSO, which is set to 1. (n.s.: non-significant; * P<0.05, ** 
P<0.01 and *** P<0.001; n=4). 
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Figure 7.6. The effect of synthesized tetrahydrocarbazole analogues on γ-secretase cleavage activity 
in HEK293-C99 cells 
(a) Relative Aβ38, Aβ40 and Aβ42 levels after 16 h treatment with select tetrahydrocarbazole derivatives at 
10 µM in HEK293-C99 cells. Sulindac sulfide (50 µM), Bepridil (30 µM) and DAPT (10 µM), respectively, a γ-
secretase modulator, an iGSM, and a γ-secretase inhibitor, were used as positive controls. All values are 
normalized to the value of DMSO, which is set to 1. (n.s.: non-significant; * P<0.05, ** P<0.01 and *** 
P<0.001; n=2). 
(b) Relative Aβ42/Aβ40 ratios calculated from (a). Treatment with tested analogues does not alter 
Aβ42/Aβ40 ratios, whereas positive controls Sulindac sulfide and Bepridil, respectively lead to a significant 
decrease and increase in Aβ42/Aβ40 ratios. All values are normalized to the value of DMSO, which is set to 
1. (n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=2). 
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Figure 7.S1. The list of commercially available tetrahydrocarbazole analogues 
Shown are 38 tested commercially available tetrahydrocarbazole analogues. Next to their chemical structure 
and physical properties, the measures for their activity in different assays are presented with their 
corresponding normalized values for: CCh-evoked calcium release peak; mitochondrial membrane potential 
(TMRM); and the levels of three different secreted Aβ peptides (measured at 10 µM). 
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Figure 7.S2. The list of synthesized tetrahydrocarbazole analogues 
Shown are 23 strategically synthesized tetrahydrocarbazole analogues. Next to their chemical structure and 
physical properties, the measures for their activity in different assays are presented with their corresponding 
normalized values for: CCh-evoked calcium release peak; mitochondrial membrane potential (TMRM); and 
the levels of three different secreted Aβ peptides (measured at 10 µM).  
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Figure 7.S3. The effect of commercially available tetrahydrocarbazole analogues on Aβ production 
Relative Aβ38, Aβ40 and Aβ42 levels are decreased after 16 h treatment with commercially available 
tetrahydrocarbazole analogues at 10 µM in HEK293 cells coexpressing APPsw and PS1-M146L. Sulindac 
sulfide (50 µM) and DAPT (10 µM), respectively, a γ-secretase modulator and a γ-secretase inhibitor, were 
used as positive controls. All the values are normalized to the value of DMSO, which is set to 1. (n.s.: non-
significant; * P<0.05, ** P<0.01 and *** P<0.001; n=2). 
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Figure 7.S4. The effect of commercially available tetrahydrocarbazole analogues on Aβ42/Aβ40 ratio 
Relative Aβ42/Aβ40 ratios calculated from figure 7.S2. Treatment with the majority of the lead structure 
derivatives does not alter the Aβ42/Aβ40 ratio, whereas the positive control Sulindac sulfide (but not DAPT), 
significantly lowers the Aβ42/Aβ40 ratio. All values are normalized to the value of DMSO, which is set to 1. 
(n.s.: non-significant; * P<0.05, ** P<0.01 and *** P<0.001; n=2). 
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7.6 Supplementary Material 
 
Commercially available compound library and derivatives: The DIVERSet® compound 
library and further commercially available tetrahydrocarbazole analogues and related 
structures were obtained from ChemBridge (ChemBridge Corp., San Diego, CA). The 
database for the library compounds and the tested analogues are available at 
http://www.chembridge.com and https://www.hit2lead.com 
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8 General Discussion 
 
8.1 The role of presenilin holoprotein upregulation in AD-associated calcium 
dyshomeostasis 
 
In the first part of this work, we could shed light on some of the controversies regarding 
the role of presenilins in the ER calcium homeostasis. Our results suggest that conditions 
enhancing the amount of PS1 holoprotein result in reduced ER calcium content. 
Therefore, in view of the impaired PS autoendoproteolysis caused by FAD-PS mutations 
and the leak channel property of PS holoprotein, we propose that the consequent 
increased stability and/or accumulation of PS holoprotein may directly contribute to AD 
pathogenesis by affecting the ER calcium homeostasis. Considering the strong 
concentration gradient of calcium ions between ER and cytosol, in addition to very low 
PS holoprotein expression levels under physiological circumstances, even minor 
upregulation in the PS holoprotein level may alter intracellular calcium signaling 
remarkably. 
 
Particularly, in HEK293 cells carrying FAD-PS1 mutations, we detected lowered ER 
calcium release in response to stimulation with TP and BK. However, amplified CCh-
induced ER calcium response was detected in the FAD-PS1 cells. Here we argue that in 
the case of stimulation with TP and BK, lowered ER calcium content is the cause for the 
attenuated calcium release from ER. However, in the event of stimulation with CCh, 
compensatory mechanisms seem to be in action that can mask the lowered ER calcium 
content of FAD-PS1 cells. Stimulation with CCh typically generates higher levels of IP3 
molecule compared to stimulation with BK [279]. The latter in combination with FAD-
PS1-mediated oversensitized IP3Rs [69, 235], result in amplified calcium release from ER 
upon CCh stimulation. Despite the contradicting data around this topic, evidence in 
support of our hypothesis comes from the studies that detected decreased ER calcium 
load by directly measuring the absolute amount of ER calcium in cells harboring FAD-PS 
mutations [233, 234].  
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We also observed that treatment of HEK293 cells with three different γ-secretase 
inhibitors result in lowered calcium release from ER, accompanied by elevated levels of 
PS1 holoprotein, presumably due to inhibition of PS autoendoproteolysis. This indicates a 
potentially neglected side effect for this class of drugs, which may unexpectedly even 
accelerate the disease progression. Thus, in view of these findings we suggest that the 
development of medicines targeting PS molecules and/or γ-secretase complex (e.g. γ-
secretase inhibitors and modulators), should carefully address their impact on intracellular 
calcium homeostasis as well. 
 
Within this study, we could detect elevated levels of PS1 holoprotein in the postmortem 
brain samples of AD patients carrying FAD-PS1 mutations. On the basis this finding, one 
could argue that in the AD population carrying FAD-PS mutations, increased PS 
holoprotein levels may underlie the AD-associated impairments of ER calcium 
homeostasis. On other hand, regarding sporadic AD and FAD-APP cases, other 
pathological mechanisms can potentially exist which may eventually give rise to such 
impairments in the intracellular calcium homeostasis [291]. However, in the case of 
sporadic AD, as the disease follows a slower progression, those underlying mechanisms 
responsible for calcium dyshomeostasis are likely to have more subtle effects. 
 
Overall, with respect to the passive calcium leak channel activity of PS holoprotein on the 
ER membrane [228], we demonstrated that conditions decreasing the autocatalytic 
function of PS holoprotein result in accumulation of its holoprotein form, which in turn 
affects the ER calcium homeostasis. Within this study, a number of different approaches 
were used to mimic the accumulation of PS holoprotein (overexpression of wild type and 
mutant PS1 variants, treatment with γ-secretase inhibitors, and the knockdown of PEN-2). 
These approaches resulted in attenuated ER calcium response, likely because of enhanced 
continuous calcium leakage from ER into cytosol and the subsequent decrease in the ER 
calcium load. 
 
Given that numerous mechanisms have been associated with the expression of FAD-PS1 
mutants (e.g. modulated IP3R, RyR, SERCA, PS holoprotein leak channel activity and 
CCE) [255], one may argue that such mechanisms are downstream effects of PS1 
holoprotein accumulation, developed to compensate the decrease in the ER calcium load. 
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8.2 Development of a high-throughput FRET-based calcium imaging assay 
for drug screening in AD 
 
Based on our findings regarding the role of presenilins in calcium signaling and the 
growing evidence towards the involvement of impaired intracellular store calcium 
homeostasis in the pathogenesis of AD, we took a calcium-signaling-targeted approach 
for AD drug discovery [332, 337].  
 
To that end, we combined intracellular calcium dyshomeostasis as a novel target for drug 
screening with an innovative FRET-based confocal calcium imaging technique in a fully 
automated high-throughput manner using Opera® system. This assay targets calcium 
dysregulation in the ER as a unique approach for AD drug discovery. In contrast to the 
mainstream AD drug development paradigms, our approach targets one of the earliest (if 
not the most upstream) events in the AD progression, long before the appearance of 
characteristic disease hallmarks and cognitive deficits. The latter promises a huge clinical 
potential for prevention, halting, or reversal of AD. To the best of our knowledge, the 
possibility of normalizing the impaired ER store calcium homeostasis has never been 
examined in high-throughput drug discovery of neurodegenerative diseases [332, 337]. 
 
Using the developed assay, we can measure the basal cytosolic calcium concentrations 
and follow the rises in calcium levels (e.g. ER calcium release), simultaneously in 
hundreds of single cells expressing a genetically-encoded calcium indicator. For the 
purpose of this assay, it was essential that the Opera® system is equipped with a dispenser 
unit, which allowed performing rapid automated dispensing of reagent jets to individual 
wells during calcium measurements with no time lag between dispensing and imaging. 
This was necessary for kinetic measurements that require rapid imaging with no delay 
post dispensing, e.g. fast agonist-induced calcium release [332, 337]. 
 
The single-cell-based feature in this assay is particularly advantageous, as it enables the 
detection of minimal changes in calcium dynamics that may not be detectable in 
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conventional single-well-based calcium measurement screening technologies. Moreover, 
the ability to follow calcium transients in individual cells allows distinguishing distinct 
cell subpopulations by applying different filtering parameters in image analysis, which is 
another limiting factor in the single-well-based calcium imaging assays [332, 337]. 
 
Traditionally, small calcium dyes are used for conventional calcium imaging. However, 
their use in high-throughput fashion is prone to a number of disadvantages associated 
with long-term dye toxicity, loading, washing and leakage. Importantly, the use of 
genetically-encoded calcium sensors solves the cytotoxicity issue and enables monitoring 
calcium transients over extended periods and following both slow and fast kinetic events.  
 
Here, the developed assay was validated for CCh-induced calcium release in double-
stable HEK293 line transfected with a FAD-PS1 variant and YC3.6. The assay proved to 
be optimal for high-throughput screening, as it provided a reliable window of separation 
between positive and negative controls, reflected by the robust Z’-factor > 0.8. 
 
While the HTS assay was primarily developed for large-scale compound screening 
purposes, potentially it can be applied to other applications as well. For example, the 
assay in its current form can be easily adapted to high-throughput RNAi screens. 
Performing siRNA screens on the basis of the established HTS assay would identify 
potential novel genes and pathways that are involved in the FAD-PS1 associated ER 
calcium dyshomeostasis. Such genes and pathways may even serve as future novel AD 
drug targets. Furthermore, the established assay has the potential of being employed in 
the early diagnostics of AD. A recent study shows that intracellular calcium homeostasis 
is impaired in the peripheral cells (e.g. lymphocytes) derived from patients with mild 
cognitive impairment and sporadic AD [46]. According to this finding, it is feasible to 
utilize the established automated calcium imaging assay for monitoring such calcium 
disturbances at early stages of the disease. However, due to issues associated with the 
lack of adhesion in lymphocytes and the difficulties in introducing YC3.6 calcium 
indicator into primary cells, further adjustments are necessary to optimize the assay for 
automated diagnostic purposes. 
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Although for the purpose of this project we particularly focused on the use of FAD-PS 
expressing HEK293 cells in the assay, nevertheless, the developed HTS system provides 
a broad potential to be applied to sporadic AD and many other disease conditions 
associated with impaired calcium homeostasis. Amongst them are many 
neurodegenerative and cardiac disorders and aging. 
 
As opposed to the bulk of current AD drug discovery approaches that largely rely on 
“target-based” assays, here we developed a “phenotypic” screening approach. Various 
mechanisms have been proposed to underlie the FAD-PS1-mediated enhancement of the 
ER calcium release, e.g. enhanced IP3 and ryanodine receptor (RyR) channel activities, 
altered SERCA function, decreased store-operated calcium entry (SOCE), and loss of PS 
holoprotein passive calcium leakage activity [255]. Irrespective as to whether those are 
the primary causative factors or only downstream secondary phenomena, the present 
phenotypic assay enables identification of all compounds that can reverse the exaggerated 
agonist-evoked ER calcium release phenotype in HEK293 cells expressing FAD-PS, 
independent of their mechanism of action. [332, 337]. 
 
Apart from the oversensitivity of IP3R itself [69, 235], several upstream components of 
IP3R-mediated calcium response are also affected in AD, e.g. G-protein coupled receptors 
(GPCR) generally [355], and muscarinic receptors particularly [356], G-proteins [357], 
and PLC [200]. The combination of those effects in cells expressing FAD-PS1-linked 
mutations result in an exaggerated IP3R-mediated calcium response compared to wild 
type PS1 expressing cells [223]. Since the hits from the screen may potentially target any 
of those upstream components, a phenotypic “multi-targeted” compound screening 
approach as such, provides the advantage of jointly addressing several AD aspects. 
Considering the recent failure of AD drug candidates identified from target-based 
approaches, such a multi-targeted phenotypic drug discovery assay may present a 
promising alternative for identification of novel drugs for AD [332]. 
128 | DISCOVERY AND CHARACTERIZATION OF NOVEL DRUGS FOR TREATMENT OF AD FROM A HTS 
 
8.3 High-throughput screening of compound libraries, discovery and 
characterization of novel drugs for treatment of AD 
 
The developed assay was initially employed in a medium-size pilot screen with a library 
of ion channel ligands, from which Bepridil was identified as an active hit. The ion 
channel ligand library was chosen based on the interdependence of ER calcium with basal 
cytosolic calcium levels and calcium influx. Moreover, we postulated that calcium 
channel blockers might potentially modulate the activity of ER calcium channels or 
passive calcium leakage through presenilin holoprotein. We found that Bepridil could 
reverse the FAD-PS1-dependent potentiation of agonist-evoked ER calcium release. 
 
Interestingly, Bepridil was recently proposed as an AD therapeutic drug candidate based 
on the finding that it lowers Aβ peptide production. We confirmed those findings and 
demonstrated that Bepridil attenuates Aβ production by shifting the amyloidogenic β-
cleavage of APP towards non-amyloidogenic α-cleavage, while simultaneously 
possessing an iGSM mode of action. In addition, we revealed that Bepridil treatment also 
results in AMPK activation. The activation of AMPK is known to increase α-secretase 
activity that accompanies decreased β-secretase activity. Therefore, we propose that 
beneficial effects of Bepridil in lowering Aβ levels could be at least partially related to 
AMPK activation.  
 
After a successful pilot screen, we subsequently performed a large-scale screen with a 
diverse compound library comprising 20,000 low-molecular-weight molecules, which 
resulted in the identification of five lead structures, one of them being 
tetrahydrocarbazoles. Characterization of this lead structure using additional AD-relevant 
secondary assays indicated a multifactorial mode of action for tetrahydrocarbazoles. This 
class of compounds was able to simultaneously normalize the ER calcium homeostasis, 
enhance mitochondrial function and lower Aβ production through decreasing β-secretase 
cleavage. 
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Notably, for two other lead structures identified in the primary screen, Phenothiazines and 
Thiazolidines, existing evidence supports the beneficial role of those compound classes 
for AD treatment [360-362]. Such indications validate the relevance our phenotypic 
screening strategy as well as the lead structures identified from it [332]. 
 
AD is a multifactorial disease, which is believed to be caused by complex interactions 
among several contributing pathomechanisms [330]. Therefore, in view of the 
multifactoriality of tetrahydrocarbazoles, we propose that this novel class of compounds 
may present the basis for an effective therapeutic modality by collectively addressing 
three central AD-associated pathological mechanisms. 
 
Based on the hypothesis that impaired calcium homeostasis is an early event in the AD 
pathology, it was anticipated that the pharmacological normalization of ER calcium 
homeostasis may prevent the appearance of late-stage AD pathologies. Indeed, 
stabilization of calcium signaling interfered with the appearance of characteristic AD 
features. In the case of Bepridil, normalization of ER calcium homeostasis led to lowered 
Aβ production by enhancing AMPK activity in a calcium-dependent manner. Similarly, 
normalization of ER calcium signaling with tetrahydrocarbazoles resulted in improved 
mitochondrial function, decreased β-secretase activity and lowered Aβ production. 
However, since the molecular targets of the identified lead structures are not yet 
determined we cannot firmly conclude whether the detected changes in APP processing 
and mitochondrial function are indeed downstream effects of the modulation of 
intracellular calcium homeostasis. 
 
While strong evidence supports the “association” of Aβ pathology with AD, the field has 
begun to question the “causative” role of Aβ in the pathogenesis of AD [363]. We could 
show that pharmacological normalization of calcium homeostasis lowers Aβ production. 
Although the field has recently faced the failure of many Aβ-focused therapeutic 
modalities, our results indicate that targeting calcium homeostasis as an upstream event 
affects the downstream Aβ pathology in AD. Even if therapeutic removal of Aβ would 
not provide the desired clinical efficacy by itself, nevertheless, Aβ pathology is indicative 
of disease progression and a relevant biomarker for AD. Hence, the identified lead 
structures ameliorate the disease hallmarks (which may not necessarily be the causes of 
AD) by targeting and normalizing intracellular calcium homeostasis. 
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Impaired maintenance of physiological intracellular calcium homeostasis is critically 
involved in the pathophysiology of many diseases and aging [35, 346, 347]. Thus, 
compounds that stabilize the intracellular calcium homeostasis may be of potential benefit 
against aging and different disease conditions such as dementia, neurodegeneration, 
central nervous system and cardiovascular disorders [315, 364]. For example, FAD-PS 
mutations are associated with dilated cardiomyopathy and in many pathological 
conditions, including cardiac hypertrophy, and the IP3R activity is altered in a number of 
neurodegenerative disorders. 
 
Therefore, targeting disrupted calcium homeostasis and pharmacologically restoring the 
physiological calcium signaling, particularly in ER, opens novel avenues to more 
efficiently treat AD and several other human diseases and conditions which are associated 
with impaired intracellular calcium homeostasis. In this work, the beneficial effects of 
identified compounds were particularly investigated and confirmed in cellular models of 
FAD. 
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